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Riassunto 
Studi epidemiologici e ricerche sperimentali hanno rivelato che il tè verde ha molte 
proprietà sia come agente antitumorale che antiinfiammatorio. Tra tutti i polifenoli 
presenti nel tè verde, molti lavori mostrano che l’epigallocatechina gallato (EGCG) è 
il principale principio attivo in quanto esso è in grado di inibire l’angiogenesi, 
l’urochinasi, le metalloproteinasi e l’induzione dell’ossido nitrico sintasi inducibile 
(iNOS). Gli effetti benefici del tè verde si pensavano essere attribuiti alle spiccate 
proprietà antiossidanti dei polifenoli in esso contenuti, ma dati ottenuti negli anni 
passati nel nostro laboratorio hanno evidenziato una diversa azione più specifica. 
Signal Transducers and Activators of Trascription (STATs) sono una famiglia di 
fattori trascrizionali che mediano l’azione di citochine coinvolte in numerose funzioni 
biologiche. Tra tutte la catechine presenti nel tè verde, solo EGCG era in grado di 
inibire l’attivazione del fattore trascrizionale Signal Transducer and Activator of 
Trascription 1 (STAT1), indotta dalla citochina interferone gamma (IFN). 
L’attivazione di STAT1, indotta da IFN, fa parte di alcune vie di trasduzione del 
segnale che innescano numerosi processi infiammatori, ed è necessaria per 
l’espressione di molteplici geni pro-infiammatori quali iNOS e il complesso maggiore 
di istompatibilità di calsse II DR alfa (MCH II DRA). La loro attivazione è stata 
riscontra in numerose malattie e EGCG, essendo in grado di inibirne l’espressione, 
risulta essere un buon coadiuvante nel trattamento di patologie infiammatorie STAT1 
dipendenti. 
15 nuove catechine gallato con struttura chimica analoga alla gallocatechina gallato 
(GCG), diastereoisomero trans dell’EGCG, sono state sintetizzate per il lavoro di 
ricerca qui proposto. Queste catechine di sintesi presentano un ridotto numero di 
ossidrili legati ai vari anelli della struttura rispetto alla GCG, composto di riferimento. 
I composti 2 e 3 presentano un minor numero di ossidrili sull’anello A, i composti 4, 
5 e 6 mostrano una riduzione di ossidrili sull’anello B, i composti 7, 8, 9 e 10 
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presentano modifiche sull’anello D, mentre i composti rimanenti portano riduzioni di 
ossidrili su più anelli contemporaneamente. 
Lo studio ha permesso di verificare: 
1) In una linea cellulare di carcinoma mammario MDA MB 231, la capacità dei 
composti di sintesi studiati di inibire l’attivazione di STAT1 indotta da IFN, 
allo scopo di individuare la porzione di molecola minima necessaria e 
sufficiente per garantirne l’attività. I dati ottenuti indicano che la presenza di 
tre ossidrili in posizione 3, 4 e 5 dell’anello B, e di almeno un ossidrile 
nell’anello D rendono le catechine capaci di inibire la fosforilazione di 
STAT1 in Tyr701 e Ser727, di bloccare il legame di STAT1 al DNA ed di 
impedire l’espressione di geni STAT1 dipendenti iNOS e MCH II DRA.  
2) La diretta interazione tra la proteina STAT1 ricombinante e le catechine 
attive. L’ipotesi che, lungo la via IFN/STAT1, il target molecolare delle 
catechine studiate potesse essere la proteina STAT1 stessa è stata verificata 
mediante Surface Plasmon Resonance (SPR), Molecular Modelling, studi di 
mutagenesi sito specifica e saggi chinasici tra la proteina ricombinate STAT1 
e l’enzima ricombinate Janus Kinase 2 (JAK2). 
I nostri dati hanno permesso di suggerire un possibile, specifico ed efficiente 
meccanismo d’inibizione dell’attivazione di STAT1, da parte delle catechine. Ciò può 
rappresentare un punto d’inizio per lo sviluppo di nuovi composti capaci di modulare 
selettivamente l’attivazione di STAT1, utili nella prevenzione o terapia di patologie 
infiammatorie.  
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Abstract 
In the last years, a great interest is emerging about green tea as a tool against human 
cancer development or inflammation, as pointed out by many reports describing the 
inhibitory action of epigallocatechin gallate (EGCG), the main polyphenol 
component of green tea, on angiogenesis, urokinase, metalloproteinases, and 
induction of inducible nitric oxide synthase (iNOS). The beneficial effect is believed 
to be due to their strong antioxidant activity. However, our laboratory evidence 
indicates the involvement of a more specific action.  
Signal Transducers and Activators of Transcription (STATs) are nuclear factors 
mediating the action of cytokines involved in various biological functions. Among a 
number of catechins present in green tea extract, only epigallocatechin gallate 
(EGCG) exerts a strong inhibitory action on interferon gamma (IFN)-elicited 
activation of Signal Transducer and Activator of Transcription 1 (STAT1).  
IFNγ-elicited STAT1 activation is important for iNOS and other STAT1 dependent 
genes expression, as major histocompatibility complex class II DR alpha (MCH II 
DRA). 
15 new compounds, obtained by chemical modification of gallocatechin gallete 
(GCG), diastereomer of EGCG, were synthesized. They present fewer hydroxyl 
groups than GCG in ring A (compounds 1, 2 and 3) or in ring B (compounds 4, 5 and 
6) or in ring D (compounds 7, 8, 9 and 10), or simultaneously in more than one ring 
(compounds 11, 12, 13, 14 and 15).  
In this work we show: 
1) The ability of some of this new synthetic compounds to inhibit IFNγ-elicited 
activation of STAT1, in human MDA MB 231 cell line, by showing the 
minimal chemical features necessary and sufficient for this activity. The 
synthetic catechins with three hydroxyl groups in 3, 4 and 5 of ring B and at 
least one hydroxyl group in ring D are able to block STAT1 Tyr701 and 
Ser727 phosphorylation, STAT1 DNA-binding and STAT1 dependent iNOS 
and MCH II DRA gene expression.  
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2) The direct interaction between STAT1 recombinant protein and the anti-
STAT1 catechins, identifying STAT1 itself as the real molecular target of 
catechins in the IFN/STAT1 pathway. This data was confirmed by Surface 
Plasmon Resonance (SPR) analysis, Molecular Modelling studies, Site-direct 
Mutagenesis,  and STAT1- Janus Kinase 2 (JAK2) kinase assay. 
In conclusion, we suggest a specific molecular mechanism of action of the catechins. 
These results may be considered the first step to the development of new anti-STAT1 
molecules, that can be used as new drugs against inflammatory processes by 
modulation of STAT1 signaling. 
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1.1 Inflammation 
 
Inflammation is a protective attempt by the organism to remove the injurious stimuli 
and to initiate the healing process. However, inflammation and repair may be 
potentially harmful. 
Inflammation is divided into acute and chronic patterns. Acute inflammation is 
relatively short duration and it is characterized by increased blood flow in the injured 
area. Leukocytes adhere to endothelium via adhesion molecules, transmigrate across 
the endothelium and migrate to the sites of injury under the influence of chemotactic 
agents. Phagocytosis of the offending agent follows, which may led to the death of 
the microorganism. During chemotaxis and phagocytosis, activated leukocytes may 
release toxic metabolites and proteases causing tissue damage.  
Chronic inflammation is considered to be low-grade inflammation of prolonged 
duration. This includes some of the most common and disabling human diseases, 
such as rheumatoid arthritis, atherosclerosis, tuberculosis, and the chronic lung 
diseases. Both acute and chronic inflammation provoke the release of mediators, such 
as interleukins, tumor necrosis factor α, interferons and platelet-derived grow factor 
that can amplify the inflammatory response and influence its evolution. 
There are two classes of anti-inflammatory agents: glucocorticoids and nonsteroidal 
anti-inflammatory drugs. Glucocorticoids inhibit phospholipase A2 , the enzyme that 
hydrolyzes the ester bond of membrane phospholipids with the release of 
arachidonate and prostaglandin production (Flower R. J., 1990).  
Non-steroid anti-inflammatory drugs (NSAIDs) are the most widely prescribed for 
inflammatory diseases, these being the most critical worldwide pathologies, whereas 
extensive effort should be paid to the development of a new therapy. It is well known 
that NSAIDs exert their anti-inflammatory, analgesic and antipyretic action by 
inhibiting the activity of cyclooxygenase (COX), the prostaglandins synthesizing 
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enzyme (Vane J.R., 1971). Although the usefulness of NSAIDs has been widely 
documented, their prolonged administration often leads to undesirable side effect, 
especially in the gastrointestinal tract (Vane J. R. et al., 2003). Consequently, in the 
last decade many efforts have been paid to find new drugs, leading to the 
development of a new class of NSAIDs with improved gastrointestinal tolerability 
(Meyer-Kirchrath J., 2000). 
 
1.2 STAT1 as a new molecular target of anti-inflammatory 
treatment  
 
One of the hallmarks of the inflammatory response is the massive synthesis of nitric 
oxide (NO) by inducible NO synthase (iNOS), the expression of which is finely up-
regulated by a number of pro-inflammatory cytokines such as interferon gamma 
(IFNγ), tumor necrosis factor alfa (TNFα) and interleukin 1beta (IL1β), together with 
gram-negative bacterical membrane-derived lipopolysaccharides (LPS) (Mariotto S. 
et al., 2004). The activation of iNOS provokes a massive production of NO which is 
deleterious for the cell. 
Pro-inflammatory cytokines and LPS exert their action by activating specific nuclear 
factors regulating the expression of inflammatory genes. Signal Transducer and 
Activator of Transcription 1 (STAT1) principally mediate the action of IFNγ, while 
the nuclear factor-kappaB (NF-κB) mediates the signaling of TNFα, IL1β and LPS. 
The modulation of these nuclear factors has recently been considered a new strategy 
in the treatment of inflammatory diseases. Although NF-κB has so far received more 
attention ( Lee J. I. et al.,1998; Zingarelli B. et al., 2003) we decided to study the 
critical role played by STAT1, which is activated in a number of related diseases 
(Carcereri de prati A. et al, 2005).    
The inflammatory response proceeds without a minimum damage to the body if 
STAT1 activation is time-spatially well regulated. However, any deregulation of 
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STAT1 activation (i.e. excessive up- or down-regulation, prolonged activation, time-
spatially erroneous activation, etc.) may cause a deleterious effect to tissue integrity 
(Lin T.S., 2000).  
STAT1 hyperactivation is one of the most relevant phenomena in many pathologies 
correlated to both acute and chronic inflammation, such as ischemia/reperfusion 
injury, unstable angina, asthma, atherosclerosis, celiac disease and psoriasis. So the 
modulation of STAT1 activation may be a promising molecular target for a new class 
of anti-inflammatory drugs.  
STAT1 protein belongs to a family of transcription factors that are inactive in the 
absence of specific receptor stimulation and are localized in the cytoplasm of 
unstimulated cells. Seven mammalian STAT proteins have been identified, STATs 1, 
3, 4, 5A, 5B are between 750 and 795 amino acids long, whereas STATs 2 and 6 are 
nearly 850 amino acids long. These proteins are activated by a different group of 
cytokines and growth factors and all these proteins share structurally and functionally 
conserved five domains: a N-terminal domain (NH2), a coiled-coil domain (CCD), a 
DNA-binding domain (DBD), a linker domain (L), a Src homology 2 (SH2) domain 
(Fig.1). The transcriptional activation domain (TAD) at the carboxy (C) terminus is 
specific for the different STATs (Fig. 2).  
  
   
 
 
Figure 1: Conserve structural domains of STAT family proteins and their function (Chen W., 2004). 
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Figure 2: STAT proteins           
 
 
                                
 
Figure 3: JAK/STAT signaling pathway (Christian W. S., 2002). 
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1.3 The JAK/STAT pathway 
 
The canonical Janus Kinase (JAK)/STAT signaling pathway is initiated by binding of 
a cytokine ligand to a cell-surface cytokine receptor (Fig. 3). The intracellular 
domains of many cytokine receptors are physically associated with tyrosine kinases 
of the JAK family. There are four mammalian JAKs (JAK1, 2, 3 and Tyk2) that are 
associated with specific cytokine receptors as can be seen in Table 1. 
Binding of ligand triggers receptor dimerization/oligomerization and allows rapid 
transphosphorylation and activation of the receptor-associated JAKs. Activated JAKs 
then phosphorylate critical tyrosine residues on the receptor, creating STAT docking 
sites. In fact this leads to recruitment of specific STATs through their SH2 domains 
followed by single tyrosine phosphorylation of the bound STAT (Darnell J. E., 1997). 
Tyrosine phosphorylation of STATs can also be stimulated by binding of growth 
factors to receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor 
or platelet-derived growth factor receptor. 
 
Table 1: Cytokines transduce their signals through specific sets of JAKs and STATs as indicated.  
Receptors Ligands Jaks kinasi STATs 
 
IFN Family 
IFNγ TYK2, JAK1 STAT1, STAT2 
IFNγ JAK 1, JAK 2 STAT1 
IL10 TYK 2, JAK 1 STAT3 
 
Gp130 Family 
IL6 JAK1, JAK2, TYK2 STAT3 
IL11 JAK 1 STAT3 
IL12 TYK2, JAK 2 STAT4 
 
γC Family 
IL2, IL7,IL15 JAK 1, JAK 3 STAT5 
IL4 JAK 1, JAK 3 STAT6 
Receptor tyrosine 
kinases 
EGF, CSF1                   STAT1, STAT3, STAT5 
PDGF  STAT1, STAT3 
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After phosphorylation, STAT proteins form homodimers via reciprocal 
phosphotyrosine-SH2 interactions. Activated STAT dimers enter the nucleus via 
Importin-α dependent transport and bind to specific DNA targets. Nuclear import of 
different STAT proteins requires different transporters (e.g., STAT3 binds to 
importin-α3, STAT1 to importin-α5).  
In order to drive gene expression, STAT proteins cooperate with numerous other 
transcription factors such as IRFs, Sp1, Jun, Fos, NF-κB and coactivators with 
functions in chromatin remodeling such as p300/CBP, PCAF, BRG1. 
Maximal transcriptional activation requires serine (S) phosphorylation of a conserved 
motif (L)P(M)SP in the STAT C terminus. Dissociation from DNA allows 
dephosphorylation of STATs by nuclear protein tyrosine phosphatases (N-PTPs), 
such as SHP2, to complete the cycle of activation/inactivation. The unphosphorylated 
dimers associate with the nuclear export factor, chromosome region maintenance 1 
(CRM1), for transport back to the cytoplasm where it can be reactivated (Meyer T. 
and Vinkemeier U., 2004) (Fig.4). 
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Figure 4: STATs at the nuclear envelope. 
(A) Carrier-dependent import. Phosphorylated STAT dimers expose a dimer-specific nuclear localization signal 
and associate with importin α. Through importin β-mediated interactions with the interior of the nuclear pore 
(NPC) this complex migrates into the nucleus. The complex disassembles after the binding of RanGTP.  
(B) Carrier-dependent export. Unphosphorylated STATs can bind to the exportin CRM1 via leucine-rich nuclear 
export signals and traverse the NPC. RanGTP enhances the interaction of CRM1 with cargo proteins. In the 
cytoplasm, the nucleotide hydrolysis of RanGTP leads to release of the cargo.  
 
 
The negative regulators of the JAK/STAT pathway are well known; they include 
suppressors of cytokine signaling (SOCSs), protein tyrosine phosphatases (PTPs) and 
protein inhibitors of activated stats (PIAS) (Greenhalgh C. J. and Hilton D. J., 2001) 
(Fig.5). 
SOCS proteins are a family of eight members, SOCSs 1 to 7 and CIS, they complete 
a simple negative feedback loop in the JAK/STAT circuit. Activated STATs 
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stimulate transcription of the SOCS genes and the resulting SOCS proteins bind 
directly phosphorylated JAKs to specifically inhibit JAK kinase activity (Starr K. et 
al., 1997). SOCS proteins can also bind phosphotyrosines on the receptors, so 
physically block the recruitment of  STATs to the receptor (Endo T. A. et al., 1997; 
Shuai K. and Liu B., 2003; Chen X. P. et al., 2000).  
PTPs, in the cytoplasm, reverse the activity of the JAKs. This class of enzymes 
includes SHP-1, SHP-2 and CD45. The best characterized of these is SHP-1, this 
contains two SH2 domains and can bind to either phosphorylated JAKs or 
phosphorylated receptors to facilitate dephosphorylation of these activated signaling 
molecules (Rane S. G. and Reddy E. P., 2000). 
In the nucleus, STAT activity is restrained by PIAS proteins. The PIAS family 
proteins are a group of 5 STAT interacting proteins that bind to activated STAT 
dimers and prevent them from binding DNA. 
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Figure 5: STAT1 cascade. a) Normal condition, all the player of STAT1 cascade are present in the resting state. 
b) Activation of IFNγ-elicited STAT1 and its up-regulation. Cellular membrane-bound IFNγ receptor (IFNGR 
1/2) recognizes, among different cytokines, specifically IFNγ. Upon recognition, IFNγ activates IFNGR1/2 
leading to activation of neighbouring JAK 1/2. Activated JAK 1/2 phosphorylate tyrosine residue(s) of 
themselves, IFNGR 1/2 and STAT1. Tyrosine-phosphorylated STAT1 forms dimers, thus achieving the capacity 
to enter the nucleus. c) Down-regulation of JAK 1/2 may be tuned by other proteins such as PIAS, PTPs including 
SHP-1 and SOCS. d) Induction of STAT1-dependent genes. Activated STAT1 recognizes the promoter regions of 
specific genes encoding proteins deeply involved in the inflammatory response such as iNOS and SOCS. 
 
 
 
 
 
1.3.1 The principal players of IFNγ-elicited STAT1 pathway  
 
IFNγ receptor belongs to the class II cytokine receptor family and has two subunits 
(Fig. 5): IFNGR1, the ligand-binding chain, also known as the α chain, and IFNGR2, 
the signal-transducing chain, also known as the β chain. IFNGR chains lack intrinsic 
kinase/phosphatase activity and so must associate with signaling machinery for signal 
transduction. The intracellular domain of IFNGR1 contains two functionally 
importance sequences: JAK1 binding motif  LPKS (Leu-Pro-Lys-Ser), a membrane-
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proximal sequence, and the STAT1 binding sites YDKPH (Tyr-Asp-Lys-Pro-His) . 
This last motif contains an essential Y440 phosphorylation site that is phosphorylated 
during signal transduction to allow STAT1 recruitment to receptor. The intracellular 
domain of IFNGR2 contains a functionally important box1/box2 sequence, required 
for Jak2 association. 
Upon interaction with IFN, IFNGR1 dimerize and become associated with two 
IFNGR2. Receptor assembly leads to activation of JAK1 and JAK2 and 
phosphorylation of  the tyrosine 440 residue on the intracellular domain of IFNGR1. 
This leads to the recruitment and phosphorylation of STAT1, which forms 
homodimers and translocates to the nucleus to activate a wide range of target genes. 
After signaling, the ligand-binding chains of receptor are internalized and dissociate; 
the chains are then recycled to the cell surface. 
 
JAKs are a family of tyrosine kinases costitutively associated with a proline-rich 
membrane proximal domain of the receptor (Ihle I. N., 2001). Upon ligand 
stimulation, receptors undergo the conformational changes that bring JAKs into 
proximity of each other, enabling activation by trans-phosphorylation (Remy I. et al., 
1999) (Fig. 6).   
There are four members of the JAK family in mammals, Jak1, Jak2, Jak3 and Tyk2. 
Jak1, Jak2 and Tyk2 are expressed ubiquitously, whereas the expression of Jak3 is 
restricted to cells of the myeloid and lymphoid lineages (Leonard W. and O’Shea J. 
J.,1998, Witthun B. A. et al., 1994).  
  
 
Introduction 
20 
 
 
Figure 6:  Mechanism of STAT1 tyrosine phosphorylation by JAK. 
 
STAT1 protein, similarly to other STATs proteins, shares structurally and 
functionally conserved five domains: 
N-terminal domain, comprising approximately 130 amino acids. Several studies 
suggest that N-terminal domain promotes cooperativity of binding to tandem GAS 
elements (Xu X. et al., 1996). Other studies have suggested that the N-terminal STAT 
domain promotes interaction with the transcriptional coactivator CBP/p300 (Horvath 
C. M., 2000), the PIAS family (Shuai K., 2000), receptor domains (Leung S. et al., 
1996), and that it regulates nuclear translocation (Strehlow I. and Schindler C., 1998). 
Coiled-coil domain consists of four α-helices (approximately amino acid 135–315). 
The crystal structures of STAT1 reveals that this domain protrudes about 80A° 
laterally from the core structure (Chen  X. et al., 1998). This forms a large 
predominantly hydrophilic surface that is available for specific interactions with other 
helical proteins such as p48/IRF9, c-Jun and N-myc (Zhang J. G. et al., 1999a; Zhu 
M. H. et al., 1999). More recently, studies have also implicated the coiled-coil 
domain in receptor binding, tyrosine phosphorylation and nuclear export (Zhang T. et 
al., 2000). 
DNA-binding domain, approximately amino acid 320–480, recognizes interferon 
gamma activated site (GAS) element and activates transcriptional activity. Since the 
DNA binding domain is likely to exhibit a different conformation prior to activation, 
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it is appealing to consider the possibility that it may have additional functions 
(McBride K. M. et al., 2000). 
Linker domain, amino acids 488–576 connects the DNA-binding domain with the 
SH2 domain. The STAT1 crystal structure reveals that helix α10 of the linker domain 
interacts with the SH2 domain, and that helix α6 interacts with strand β11 of the 
DNA binding domain (Chen X. et al., 1998). These observations suggest that DNA 
binding capacity can be regulated by structural changes in the SH2 domain. 
SH2 domain plays an important role in signaling through its capacity to bind to 
specific phosphotyrosine motifs. Consistent with this, its structure (amino acids 580–
680) is well conserved. It consists of an anti-parallel β-sheet flanked by two α-helices, 
which form a pocket. An absolutely conserved STAT1 arginine (Arg602), which 
mediates the interaction with phosphate, lies at the base of this pocket. The ability of 
this SH2 domain to recognize specific phosphotyrosine motifs plays an essential role 
in three signaling events: (1) recruitment to the cytokine receptor through recognition 
of specific receptor phosphotyrosine motifs, (2) association with the activated JAK 
and (3) STAT homodimerization (Shuai K. et al., 1994). As highlighted in the crystal 
structures of STAT1, the dimerization depends on the interaction between the SH2 
domain of one STAT monomer and the tyrosine phosphorylated tail segment of the 
other monomer. The crystal structure of STAT1 bound to DNA shows that the 
dimeric interaction between two SH2 domains are crucial for the formation of a DNA 
binding clamp wraps almost entirely around the duplex (Chen X. et al., 1998) (Fig. 
7). 
The Transcriptional Activation Domain, at carboxy-terminal domain, is poorly 
conserved among the STATs. This domain contains a critical tyrosine residue 
(Y~700) which is phosphorylated when the molecule is activated. In particular 
activated STAT1 is phosphorylated in tyrosine 701. 
TAD regulates unique transcriptional responses, but how the STAT carboxy-terminus 
regulates these responses remains to be determined. However important progress has 
been made, for example it has been determined that the transcriptional activity of 
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several STATs can be modulated through serine phosphorylation (Decker T. and 
Kovarik P., 2000; Schroeder K. et al., 2004). 
The IFNγ/JAK/STAT1 cascade appears to cross-talk with other signal transduction 
pathways in addition to STAT1, in fact IFNγ activates PI3K/Akt, MKK/ERK1/2 and 
p38 MAP kinase pathways (Nguyen H., 2001; Blanchette J., 2003) that are 
responsible for the STAT1 serine phosphorylation enhancing STAT1 transcriptional 
activity, as mentioned before. 
Since STAT1 cascade requires multiple phosphorylation steps, it is likely to be 
potentially achieved at various steps (fig. 5). As described in literature, diverse agents 
may act at multiple levels to inhibit the STAT1 signal transduction pathway such as 
JAK tyrosine phosphorylation, STAT1 serine and tyrosine phosphorylation or STAT1 
DNA binding. 
  
 
 
Figure 7: The crystal structure of the STAT1 DNA complex (Chen X., 1998). 
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1.4  Inducible Nitric Oxide Synthase 
 
Nitric oxide (NO) synthase is a widely distributed enzyme catalyzing the synthesis of 
NO from L-arginine. There are three isoforms of NO synthase encoded by distinct 
genes, including the constitutively expressed neuronal and endothelial NO synthase 
(nNOS, eNOS) and iNOS.  
iNOS is normally absent in resting cells (Kleinert H. et al., 2000). After activation of 
cells by different inducers, iNOS is expressed and is active for hours to days as a 
“high-output” enzyme (MacMicking J. et al., 1997). The high amounts of NO 
produced by iNOS may be beneficial for their microbicidal, antiviral, antiparasitic, 
and antitumoral action (MacMicking J.et al., 1997; Bogdan C., 2001). However, an 
aberrant iNOS induction (high concentrations of NO, up to millimolar concentration, 
around the site of inflammation) is likely to have detrimental consequences and 
seems to be involved in the pathology of several human diseases (Kroncke K. D. et 
al., 1998). The iNOS enzyme is expressed in various organs, including the lungs and 
intestine, where an overproduction of NO contributes significantly to vascular failure 
and end-organ damage during endotoxemia and to diseases such as asthma, short- and 
long-term lung disease, and septic shock (Barnes P. J. and Liew F. W., 1995; 
Kro¨ncke K. D. et al., 1998; Kleinert H. et al., 2000; Bogdan C., 2001). Enhanced 
iNOS expression is observed in patients with inflammatory bowel disease (Cavicchi 
M. and Whittle B. J., 1999), celiac disease (van Straaten E. A. et al., 1999), ulcerative 
colitis, and Crohn’s disease (Guslandi M., 1998). Therefore, pharmacological 
suppression of iNOS-dependent NO production may be helpful in the treatment of 
these diseases. The regulation of iNOS expression is cell- and species specific, and a 
variety of signal transduction pathways are involved (Kleinert H. et al., 2000). 
Regulation of the transcription of the iNOS gene is believed to be the most important 
control mechanism for iNOS expression. JAK/STAT pathway has been shown to be 
essential for human and murine iNOS expression (Gao J. et al., 1997; Kleinert H. et 
al., 1998; Ganster R. W. et al., 2001; Menegazzi M. et al., 2001; Yao Y. et al., 2003). 
iNOS induction in human cells seems to be partially dependent on activation of the 
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NF-κB signal pathway (Kleinert H. et al., 1998). Studies using the human iNOS 
promoter showed important regulation of the iNOS promoter activity by the 
transcription factors NF-κB, activator protein (AP) 1, and STAT1 (de Vera M. E. et 
al., 1996; Kleinert H. et al., 1998; Kleinert H. et al., 2000; Ganster R. W. et al., 2001). 
Ganster et al. (2001) described the dependence of human iNOS promoter activity on a 
composite GAS/NF-κB element located at position -5.8 kb in the human iNOS 
promoter (Ganster R. W. et al., 2001). Therefore, the IFNγ/JAK/STAT pathway 
seems to be a good target for the inhibition of human iNOS promoter activation and 
hence iNOS expression in pathologic situations. 
 
1.5  Major Histocompatibility Complex Class II  
 
The major histocompatibility complex (MCH) class II plays an important role in 
cellular immunity, recognition, and differentiation. The MHC class II (MHC II) genes 
are composed of human leukocyte antigen (HLA) -DQ, -DP, -DM and –DR, the latter 
is the most abundant form. These encode α and β chains of heterodimeric cell surface 
molecules that present processed antigens to CD4
+
 T-lymphocytes. Non-immune 
cells lack constitutive expression of MCH class II, however, in most of these cells 
MCH class II expression can be induced by IFN (Benoist C. et al., 1990; Glimcher 
L. H. et al., 1992). 
The regulation of MHC II genes occurs primarily at the transcriptional level, and a 
non DNA-binding protein, class II transactivator (CIITA), has been shown to be the 
master control factor for MHC II transcription (Rohn W. M. et al., 1996; Van den 
Else P. J. et al., 1998). The induction of MHC II genes transcription by IFN occurs 
relatively slowly and depends on the presence of the transcription factors STAT1 
(Meraz M. A. et al., 1996). STAT1 induces transcription of CIITA by direct binding 
to CIITA promoter. CIITA is both essential and sufficient for MHC II expression 
(Steimle V. et al., 1994). 
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High expression of MHC class II molecules has been postulated to be involved in the 
progression of various inflammatory diseases, such as rheumatoid arthritis, insulin-
dependent diabetes mellitus, inflammatory bowel disease and multiple sclerosis 
(Grusby M. J. et al., 1995). Indeed MHC II expression was found on the endothelium 
in atherosclerotic lesions obtained from patients who died of cardiovascular or 
neurologic diseases (Van der Wal A. C. et al., 1992). An increased expression of 
MHC II molecules in arterial tissue from transplanted hearts was predictive of 
arteriosclerosis and graft failure (Labarrere C.A. et al., 1997).  
Hence MCH II expression in non-immune cells may indicate an inflammatory state, 
which can compromise the integrity of the tissue. So the inhibition of this gene 
expression can improve organ condition.  
 
 
1.6 The Catechins of Green Tea 
 
Green tea is tea made solely with the leaves of Camellia sinensis that have undergone 
minimal oxidation during processing. There are two major varieties that characterize 
this species: Camellia sinensis var. sinensis and Camellia sinensis var. assamica, that 
are members of the Theaceae family.
 
Green tea originates from China and has become associated with many cultures in 
Asia from Japan and South Korea to the Middle East. Many varieties of green tea 
have been created in countries where it is grown. These varieties can differ 
substantially due to variable growing conditions, processing, and harvesting time. Tea 
is manufactured in three basic forms: black tea (78%), green tea (20%) and oolong tea 
(2%). Unlike black and oolong tea, green tea production does not involve oxidation 
of young tea leaves. Green tea is produced from steaming fresh leaves at high 
temperatures, thereby inactivating the oxidizing enzymes and leaving the 
polyphenoles content intact.  
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Thus, green tea extract (GTE) is rich in powerful anti-oxidant polyphenoles. The 
polyphenoles found in tea are more commonly known as catechins and comprise 30–
40% of the extractable solids of dried green tea leaves.  
The main catechines in green tea are epicatechin (EC), epicatechin-3-gallate (ECG), 
epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG) (Fig. 8). EGCG, 
found in the highest concentration in green tea, is the most active and best researched 
of all green tea ingredients.  
Of all the teas consumed in the world, green tea is well studied for its health benefits 
(Mukhtar H. and Ahmad N., 1999). Green tea is generally considered a safe, non-
toxic beverage and its consumption is usually without side effects. Several 
epidemiological investigations in various countries reveal beneficial effects of green 
tea (Hirvonen T. et al. 2000; Klatsky A. L. et al. 1993).  
Green tea polyphenols have demonstrated significant anti-oxidant, anti-carcinogenic, 
anti-inflammatory, thermogenic, probiotic and anti-microbial properties in numerous 
human, animals and “in vitro” studies (Choi Y. B. et al. 2004; Crespy V. and 
Williamson G., 2004; Kakuda T., 2002; Sung H. et al. 2000). It has been 
demonstrated that ingestion of green tea significantly increased human plasma anti-
oxidant capacity “in vivo” (Serafini M. et al. 1996). Tea polyphenols have also been 
noted to induce apoptosis and cell cycle arrest in a wide array of cell lines (Levites Y. 
et al. 2002) thus retarding the growth and development of neoplasms. In addition, the 
protective effects of tea catechines were evaluated by the attenuation of nitric oxide 
formation from inducible NO synthase (Chan M. M. et al. 1997).  
The molecular basis of the action of this catechins has for long time been elusive. 
Recently some hints on the possible molecular mechanism of the antitumor or anti-
inflammatory effects of green tea have emerged: EGCG inhibits urokinase (Jankun J. 
et al., 1997), an enzyme indispensable for tumor invasion and metastasis, and 
angiogenesis (Cao Y., 1999), which is crucial for all types of tumor. In addition, 
EGCG efficiently suppresses the activity of matrix metalloproteinase-2 and -9, 
essential for tumor cells in cutting through basement membrane barriers (Liotta L. A. 
et al., 1980; Lin Y. L. and Lin J. K., 1997), thus leading to an efficient inhibition of 
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angiogenesis. Unlike to our cellular system, in the macrophage-derived cell line 
EGCG was found to exert a strong inhibitory action on NF-κB activation (Gupta S. et 
al., 2004), this seem to indicate that EGCG exerts a distinct action on the nuclear 
factor activation in different cells lines. EGCG also blocks the induction of 
expression of iNOS in lipopolysaccharide (LPS) activated mouse macrophages 
(Moncada S., 1992).  
Studies with [
3
H]EGCG, labeled with 
3
H, shows the distribution of [
3
H]EGCG in 
mouse organs by oral administration. Radioactivity was found in various organs as 
digestive tract, lung, breast, liver, pancreas, skin, kidney, brain, uterus, ovary and 
testes. This indicated that [
3
H]EGCG was incorporated into cells of organs, in 
particular these studies showed that radioactivity was incorporated into cytosol and 
nuclei of cells (Okabe S. et al., 1997). 
 
 
Figure 8 Structure of catechins present in Green Tea leaves. 
D 
D 
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1.7  EGCG inhibits JAK/STAT1 pathway 
 
Our previous study examined the inhibitory action of catechins of Green Tea on 
IFNγ-elicited STAT1 activation (Menegazzi M. et al., 2001). Among all green tea 
catechins, only EGCG, added to MDA MB 231 cells one hour before the induction 
with IFNγ, inhibited the STAT1 activation dose-dependently; the estimated value of 
the concentration giving 50% inhibition (IC50) was about 10 µM. On the contrary 
EGCG, in this cell system, failed to inhibit NF-κB, a transcriptional factor activated 
by a mix of cytokines: TNFα, IL1β, LPS and IFNγ.  
Western blot analyses showed that EGCG, dose dependently, reduced the amount of 
tyrosine phosphorylation. 
We believed that EGCG may be a promising candidate as a drug modulating STAT1 
signaling devoid of undesirable side effects.  
 
 
1.8  The synthetic catechins 
 
Some catechins were synthesized by the group of prof. Sergio Romeo, Faculty of 
Pharmacy, University of Milan. These new synthetic compounds were analogous to 
Gallocatechin gallate (GCG; 2S, 3R), which is the trans diastereomer of 
Epigallocatechin gallate (EGCG; 2R, 3R). GCG was easier to synthesize and it is 
more stable than cis diastereomer (EGCG), in fact high temperature converts EGCG 
into GCG.  
EGCG and GCG are characterized by a benzyl ring (ring A) with two hydroxyl 
groups in position 5 and 7, a pyranose ring (ring C), fused with the previous ring, 
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which binds in position 2 a second benzyl ring (ring B), with three hydroxyl groups in 
3, 4 and 5, and in position 3 a gallate group. In this work the benzyl ring of gallate 
group is called ring D. In EGCG the ring B and gallate group are in cis conformation, 
while in GCG are in trans conformation (Fig. 9).  
The synthetic catechins are racemic mixture (2S, 3R; 2S, 3S) and have fewer  
hydroxyls than GCG in ring A, or ring B, or D or simultaneously in multiple rings; 
this aspect will be described in results section. 
 
          
 Figure 9: Structure of EGCG and GCG. 
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Previous data in our laboratory, as briefly mentioned in introduction section, have 
demonstrated that, among all catechins present in green tea leaves extract, only 
EGCG is able to inhibit IFN-elicited STAT1 activation, a transcriptional factor that 
plays a pivotal role at the early phase of the inflammation in regulating the expression 
of a number of inflammation related genes (Carcereri de Prati A. et al., 2005). The 
inflammatory response is closely related and modulated by the action of cytokine and 
pro-and anti-inflammatory mediators. The loss of this homeostasis is crucial for the 
onset of chronic inflammatory diseases. In literature it is reported that the beneficial 
action of green tea dinking can be extended to inflammatory disease.  
In this work 15 synthetic catechins, obtained by chemical modification of GCG, 
diastereomer of EGCG, will be studied to identify the minimal structural feature that 
preserve the anti-STAT1 activity. The reduced number of hydroxyl groups in rings A, 
B, D and simultaneously in more rings will be considered, and the activity of these 
modifications in IFNγ-elicited STAT1 pathway and in STAT1 dependent genes 
induction will be evaluated.  
Since STAT1 cascade is up and down regulated in a complex manner, STAT1 
modulation can be potentially achieved at various steps. In this work a possible 
moleculer target of these compounds in the IFN/JAK/STAT1 pathway will be 
investigated. Several considerations were assumed and a possible direct interaction 
between some catechins and STAT1 protein will be verified by Surface Plasmon 
Resonance and molecular modelling analysis.  
In the future, the possibility to know the chemical features for anti-STAT1 activity 
and the putative interaction site of the molecular target may be useful to synthesize 
new anti-inflammatory drugs with specific effect on modulation of STAT1 signaling, 
without undesirable secondary effects of actually used anti-inflammatory drugs.
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3.1  Materials 
Chemical reagents were purchased from Sigma-Aldrich Company, Milan, Italy, 
unless otherwise specified.  
3.2 The catechins 
Epigallocatechin gallate (EGCG) and Gallocatechin gallate (GCG) were purchased 
from Sigma-Aldrich, while the synthetic catechins (compounds 1-15) were prepared 
by the group of prof. Sergio Romeo, Faculty of Pharmacia, University of Milan, 
modifying two synthetic methods reported in literature (Li L. And Chan T. H., 2001; 
Zaveri N. T., 2001).  
3.3 Cells culture 
Human mammary carcinoma cell line (MDA MB 231, American Tissue Culture 
Collection) were cultured in Dulbecco Modified Eagle’s Medium (DMEM, 
BioWhittaker, Cambrex Bio Science, Belgium) supplemented with 10% fetal bovine 
serum (FBS, Biowitthaker, Cambrex Bio Science, Belgium), gentamycin 40 µg/ml, 
penicillin 100 UI/ml and streptomycin 100 µg/ml in a humidified atmosphere of 95% 
air, 5% CO2 at 37°C. Cells were plated onto 6 cm diameter dishes for Electrophoretic 
Mobility Shift Assay (EMSA) and for RNA extraction, and 10 cm diameter dishes for 
Western Blot. At 70% confluence cells were cultured in serum free DMEM for 3-4 h 
prior to exposure to different compounds. After 1h of pre-treatment in the presence of 
different concentration of catechins, the activation of  STAT1 transcription factor was 
elicited by addition of IFN (30 ng/ml). The cells were harvested after 1 hour for 
EMSA and Western Blot analysis or 30 hours for Real-Time PCR experiments. 
For protein extraction the cells were washed in cold phosphate saline buffer (PBS, 
BioWhittaker, Cambrex Bio Science, Belgium) to stop the reaction, harvested by 
scraping, centrifuged for 5 minutes at 1500 x g and the pellets were stored at -80°C 
until use. 
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3.4 Nuclear extracts 
Nuclear extracts were prepared from cultured cells according to Osborn et al. (Osborn 
et al., 1989). Cellular pellets were solubilized for 10 minutes at 4°C in 20-30 µl of a 
strongly hypotonic solution containing a detergent, to break down the membrane 
phospholipids, (HEPES pH 7.9 10 mM,  Nonidet-P40 0.1%, KCl 10 mM,  MgCl2  1.5 
mM, DTT 0.5 mM). The solution was added of protease inhibitors: complete EDTA-
free Protease Inhibitor (Roche) 1X, 10 g/ml leupeptin, 5 g/ml antipain and 
pepstatin, 1 mM PMSF. This hypotonic solution allowed water to go into the cells, by 
osmosis, so that the cells broke out. Lysed cells were centrifuged at 4°C for 10 
minutes at 2300 x g and supernatant, containing membranes and cytosolic fraction, 
was discarded. Pellets of cell nuclei were suspended for 15 minutes in 10-15 µl of 
hypertonic solution (HEPES pH 7.9  20 mM, NaCl 420 mM, MgCl2 1.5 mM, 
Glycerol 25%, EDTA  0.2 mM, DTT 0.5 mM) containing a mixture of proteases 
inhibitors: complete EDTA-free protease inhibitors (Roche) 1X, leupeptin 10g/ml, 
antipain and pepstatin 5g/ml, PMSF 1 mM. This last solution brought, by osmosis, 
water out of nuclei so they were squeezed and allowed to release nuclear proteins. 
The samples were centrifuged at 25000 x g for 30 minutes at 4°C, the supernatants 
containing nuclear proteins were stored at -80°C until use. 
3.5 Quantification of protein concentration 
Protein concentration in the nuclear extracts was determined using the Bradford 
method (Bradford, 1976). 
The Bradford assay involves the binding of Coomassie Brilliant Blue G-250 dye to 
proteins. The dye exists in three forms: cationic (red), neutral (green), and anionic 
(blue); when the dye binds to proteins, it is converted to a stable blue form (max at 
595 nm). The quantity of proteins can be estimated by determining the amount of dye 
in the blue form, this is usually achieved by measuring with spectrophotometer 
(Beckman DU650) the absorbance of the solution at 595 nm and comparing this to a 
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standard curve generated by the reaction of known amounts of a standard protein 
Bovine Serum Albumin (BSA). 
3.6 Electrophoretic mobility shift assay (EMSA) 
Using non-denaturing polyacrylamide gel electrophoresis, 
32
P end-labeled DNA 
fragment, when binds specifically to a protein, retards its electrophoretic mobility 
showing discrete bands corresponding to the individual protein-DNA complexes.  
The double stranded oligonucleotide, containing the STAT1 binding site (sis-
inducible factor-binding recognition element, SIE/M67) from the c-Fos promoter (5-
GTCGACATTTCCCGTAAATCG-3)  (Wagner B. J. Et al., 1990) was purchased 
from MWG Biotech. The lyophilized oligonucleotide was solubilized in Tris-EDTA 
(100 pmol/µl) and 5 pmol of forward and reverse oligonucleotides were annealed at 
95°C in Tris HCl 1M pH 8, EDTA 50 mM and NaCl 5M. Then it was radiolabeled 
with -32PATP (PerkinElmer) and T4 Polynucleotide Kinase (PNK, USB 
Corporation, Ohio, USA). The T4 polynucleotide kinase catalyzes the transfer of the 
terminal pohosphate of ATP to 5 hydroxyl termini of DNA. The oligonucleotide (10 
pmoles) was combined with T4 PNK buffer (10 X) 5 µl, T4 PNK 3 U/µl, -32PATP 
20 pmoles and water up to 50 µl. The mixture was incubated at 37°C for 30 minutes 
and the reaction was terminated by heating at 65°C for 5 minutes. The 
32
P end 
labelled oligonucleotide was purified from precursor 
32
P ATP by Sephadex G-50 
column (GE Healthcare).  
10 g of nuclear extract were incubated at room temperature for 20 min with 2-5 x 
10
4
cpm of the 
32
P-labeled double stranded oligonucleotide, in a 15 l of reaction 
mixture containing HEPES 20 mM pH  7.9, KCl 50 mM, glycerol 10%, DTT 0.5 
mM, EDTA 0.1 mM, poly(dI-dC) 1 g, salmon sperm DNA 1 g. Poly(dI-dC) and 
salmon sperm DNA were added to reduce proteins’ non-specific bonds to the 32P-
labeled DNA. Products were fractioned by electrophoresis on a non denaturing 5% 
polyacrilamide gel in TBE (Tris base 50 mM, Boric acid 50 mM, EDTA 0.5 mM). 
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The gel was previously balanced for 30 minutes at 100 Volt and it was carried out in 
half past two hours at 140 Volt. At the end of the electrophoresis the gel was dried by 
gel dryer (BioRad) for 40 minutes and exposed to a photographic plate Kodak X-AR. 
The intensity of the retarded bands was measured with a Phosphoimager (Molecular 
Dynamic, Milan, Italy).  
3.7 Western Blot 
The Sodium Dodecyl Sulphate – Polyacrilamide Gel Electrophoresis (SDS-PAGE) 
followed Laemmli’s method (Laemmli, 1970). 
Cells were lysed on ice with HEPES 20 mM pH 7.4, NaCl 420 mM, Nonidet P40 1%, 
EGTA 1 mM, EDTA 1 mM and complete EDTA-free protease inhibitors (Roche) 1X 
for 20 minutes, and centrifuged  at 4°C for 30 minutes at 25000 x g. Pellets were 
discarded and supernatants were store at –80°C until use. Total cellular proteins (40-
50 µg/lane) were added of reducing buffer (Sample Buffer: Tris HCl 1 M pH 6.8, 
SDS 20%, glycerol 20%, bromophenol blu 0.25% and β-mercaptoethanol 5%), 
denatured by boiling for 5 minutes and immediately cooled on ice for 5 minutes. The 
samples were fractionated by SDS-PAGE in a 7.5% gel. A marker of known 
molecular weight (Rainbow Molecular Weight Marker, Amersham Biosciences) was 
also fractionated in the same gel. The electrophoresis was performed in running 
buffer (Tris HCl 25 mM pH 8.3, Glycin 192 mM, SDS 0.1%) at 15 mA until the 
stacking gel was passed, and at 25 mA in the running gel. Proteins were 
electroblotted onto PVDF (polyvinyldene fluoride) membrane (Immobilion P, 
Millipore, Bedford, MA, USA), previously activated 1 minute in methanol, by 
BioRad Mini Protean II TM system for 1 hour at 300 mA on ice in the transfer 
solution (Tris HCl 25 mM pH 8.3, Glycine 192 mM, Methanol 10%). The 
membranes were incubated with a blocking solution (Albumin Bovine Serum 5%, 
Tris HCl 10 mM pH 7.5, NaCl 100 mM, Tween 20 0.1%) for 1 hour at room 
temperature under agitation. Then they were incubated over night at 4°C under 
agitation with a primary polyclonal antibody anti-phosphoSTAT1 Tyr701 (Cell 
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Signaling Technology, MA, USA) diluted 1:700 in blocking solution or with a 
polyclonal antibody anti-phosphoSTAT1 Ser727 (UPSTATE Biotechnology) diluted 
1:300 in blocking solution. The membranes were washed three times for 10 minutes 
with washing solution (Tris HCl 10 mM pH 7.5, NaCl 100 mM, Tween 20 0.1%) and 
incubated with a secondary antibody anti-rabbit IgG-peroxidase conjugate (Cell 
Signaling Technology, MA, USA) diluted 1:2000 in blocking solution for 1 hour at 
room temperature under agitation. Membranes were washed again three times for 10 
minutes to dry out excess of the antibody. 
The immunoreactive proteins on the blot were detected using “Immun-Star™ 
WesternC™ Chemiluminescent Kit” (BIO RAD), an enhanced chemiluminescence 
detection system, by Bio-Rad ChemiDoc XRS. 
Following the analysis of phosphorylated STAT1, the blots were stripped and 
reprobed with anti-Total STAT1 antibody (Santa Cruz Biotechnology, CA, USA) 
diluted 1:1000. 
3.8 Real-Time PCR  
MDA MB 231 cells cultured in 6 cm diameter dishes (2.5 x 10
6
 cells) were processed 
to purify total RNA using RNeasy® Mini Kit (QIAGEN). The biological samples 
were lysed and homogenized in the presence of a highly denaturing guanidine-
thiocyanate-containing buffer, which immediately inactivated RNase to ensure 
purification of intact RNA. Etanol was added to provide appropriate binding 
conditions, and the sample was applied to an RNeasy Mini spin column, where the 
total RNA bound to the membrane while contaminant were efficiently washed away. 
High quality RNA was then eluted in 60 µl RNase-free water. 
Purified RNA was diluted 1:30 in RNase-free water in quartz cuvette, the 
concentration of RNA was determined measuring the absorbance at 260 nm 
(absorption spectrum of each sample 210-310 ; peak-point at 260) in Beckman DU650 
spectrophotometer. 
To perform Real-Time PCR using RNA as a starting template, RNA had first to be 
reverse transcribed into cDNA. For generating first-strand cDNA to use in Real-Time 
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quantitative PCR, SuperScript® VILO cDNA Synthesis Kit (Invitrogen) was used. 
As indicated in guidelines, 1 µg of RNA was combined in a tube on ice with 2 µl of 
SuperScript Enzyme Mix, which included SuperScript RT enzyme and recombinant 
ribonuclease inhibitor, and with VILO reaction mix, which included random primers, 
MgCl2, and dNTPs in a buffer formulation that had been optimized for RT-PCR . 
Finally was added free water up to 20 µl. The reverse transcription was performed 
with Rotor Gene 6000, Corbett machine, using the following program: 10 minutes at 
25°C, 60 minutes at 42°C and 5 minutes at 85°C to block reaction.    
Real-Time PCR was performed using QuantiTect® SYBR® Green PCR kit 
(QIAGEN). This kit was composed by a PCR Master Mix containing fluorescent dye 
SYBR green I, which binds all double stranded DNA molecules, emitting a 
fluorescent signal on binding; HotStarTaq DNA Polymerase which is a Taq DNA 
Polymerase modified form of enzyme, it is provided in an inactive state and has no 
enzymatic activity at ambient temperature but is activated by incubation of 15 
minutes at 95°; a buffer which contains a balanced combination of KCl and 
(NH4)2SO4 to promoting a high ratio of specific to non specific primer binding during 
the annealing step of each PCR cycle. Finally the master mix contains ROX passive 
reference dye. The fluorescence from ROX dye does not change during the course of 
Real-Time PCR, but provides a stable baseline to which PCR-related fluorescent 
signals are normalized. 
In a PCR tube 12,5 µl of QuantiTect SYBR Green PCR Master Mix were mixed with 
2,5 µl of QuantiTect Primer Assays of genes iNOS or MCH II DRA, that were ready 
to use and they were guaranteed to provide specific and sensitive quantification; 
finally, 9 µl of free water were added to the reaction mix . This mix was added to 1 µl 
of cDNA, which corresponds to 50 ng of RNA. 
The program and instrument used to occur and analyze reaction was RotorGene 6000, 
Corbett; the Real-Time PCR program was the following:  
1. 15 minutes at 95° activation HotStarTaq DNA Polymerase  
2. 15 seconds at 94° denaturation  
3. 30 seconds at 55° annealing 
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4. 30 seconds at 72° extension 
The steps from 2 to 4 were repeated 45 times. 
3.9 STAT1 expression in E. coli 
 Strains and media 
The E. coli  strains used were: 
XL1Blue (genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)]) for the amplification of the pET-22b plasmid containing 
the STAT1 sequence. 
BL21 (DE3) (genotype: F– ompT hsdSB(rB–, mB–) gal dcm (DE3)) for protein 
expression. 
Bacterial cultures were grown in Luria Bertani Broth (LB) medium. To prepare the 
LB medium, NaCl 0.5%, Tryptone 1% and Yeast extract 0.5% were suspended in 
water. The obtained solution was autoclaved at 121°C and the appropriate antibiotic,  
in this case ampicillin, was added at final concentration of 100 µg/ml. Solid cultures 
were grown in LB medium plus agar 1.5%. 
 pET-22b plasmid 
The vector used to clone and express STAT1 wild-type protein was pET-22b 
(QIAGEN).  
The plasmid size is 5493 bp. It contains a closely arranged series of synthetic 
restriction sites called “polylinker”, that are unique to the polylinker and hence 
provide a variety of targets that can be used to clone foreign DNA fragments; a bla 
sequence, coding for β-lactamase, which gives ampicillin resistance; a lacI sequence. 
This last sequence encodes the lac repressor that controls protein expression from a 
T7 promoter, which carry the lac operator. It maintains target gene transcriptionally 
silent in the uninduced state, while expression is induced by the addition of Isopropil 
β-D-tiogalattopiranoside (IPTG) to the bacterial culture.  
pET-22b enables to add a tag of six histidine residues at the C-terminus of the cloned 
protein to facilitates purification, which is performed in a Nichel Sepharose column 
by affinity chromatography. 
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Figure 10: Map of pET-22b plasmid 
 
 Amplification of STAT1 insert 
The STAT1 clone of E. coli was purchased from Invitrogen (IMAGE clone ID 
2452685, GenBank accession no. AI923499). The cDNA encoding for STAT1 
protein was amplified by PCR. Appropriate primers were designed that include 
restriction sites for two different endonuclese, at 5 and 3 ends of  inserted sequence, 
in order to have complementary sticky ends and to allow the subsequent cloning into 
the expression plasmid pET-22b. 
The primers for STAT1 cloning in pET-22b were: 
STAT1_ET-for: GGTGGTCATATGAGCACAGTGATGTTAGAC 
STAT1_ET-rev: 
AATGTCGACGGAACCACGCGGAACCAGCACTTCAGACACAGAAAT 
The CATATG and GTCGAC sequences are the restriction sites for Nde I and Sal I, 
respectively.  
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Moreover, the STAT1_ET-reverse primer allowed to include at the C-terminal end of 
the STAT1 sequence, just before the His-Tag, a sequence 
(GGAACCACGCGGAACCAG) that encodes a cleavage site for thrombin. This 
will allow to cleave the His-Tag after the protein purification.  
The PCR reaction was performed by a Mastercycler personal Thermocycler 
(Eppendorf®); the reaction mix was composed of: plasmid DNA (50 ng) ; primer 
forward (1 µM); primer reverse (1 µM); dNTPs (200 µM); Buffer 1X (stock 10X); 
Pfu DNA polymerase (Jena Bioscience) (1 unity); demineralized water DNasi free 
(up to 50 µl). 
The Pfu polymerase is an high fidelity DNA polymerase which exhibits the lowest 
error rate of any thermostable DNA polymerase. The enzyme replicates DNA at 
72°C, catalyzing the polymerization of nucleotides into duplex DNA in the 5´-3´ 
direction. Pfu Polymerase also possesses a 3´-5´ exonuclease (proofreading) activity. 
Base misinsertions that may occur during polymerization are rapidly excised by the 
proofreading activity of the polymerase. It extends at approximately 2 kb/min. 
The PCR program was the following: 
1. 5 minutes at 95° starting denaturation 
2. 60 seconds at 95°C denaturation 
3. 60 seconds at 58°C annealing 
4. 70 seconds at 72°C extension 
5. 10 minutes at 72°C final extension 
The steps from 2 to 4 were repeated 35 times. 
The STAT1 insert is composed of 581 amino acid (1743 bp), molecular weight 
67139.2 Dalton. 
After the amplification reaction, the PCR sample was run on a 0.8% agarose gel in 
TAE buffer (Tris-Acetate 40 mM pH 8, EDTA 1 mM). Ethidium bromide (0.5 µg/ml 
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final) was added to the gel. The latter is a fluorescent dye used to stain DNA, that 
intercalates between the bases of DNA. 
The samples containing DNA were mixed with a loading buffer, which contains 
glycerol to allow the sample to "fall" into the gel wells, and a tracking dye, which 
migrates in the gel and allows the visual monitoring or how far the electrophoresis 
had proceeded.  Along with the PCR reaction, a sample of a DNA size marker (1kb 
ladder, Sigma-Aldrich®) was pipetted into one of the wells to verify the correct 
length of the PCR products. 
When gel was solidified, the samples  were pipetted into the wells and a current of 80 
volt was applied. After about 40 minutes of running, the gel was observed by an 
ultraviolet transilluminator. 
The desired PCR product was purified from the gel using QIAEX®II Gel Extraction 
kit (QIAGEN). The purified DNA was resupended in Tris-HCl 10 mM pH8.5.  
 Amplification and extraction of pET22b plasmid DNA from E. coli 
cultures  
A colony of E. coli tansformed with the plasmid pET22b was incubated overnight in 
3 ml of LB medium. The cells were centrifuged at 13000 x g for 1 minute and the 
plasmid DNA was extracted by the GenElute™ Plasmid Miniprep Kit (Sigma-
Aldrich). The kit employs a modified alkaline-SDS lysis procedure followed by 
adsorption of the DNA onto a silica matrix in the presence of high salt concentration. 
Contaminant are then removed by a spin-wash step. Finally the bound plasmid DNA 
is eluted in 50 µl of Tris-HCl 10 mM pH 7.5.  
 Digestion of the STAT1 insert and of the pET-22b plasmid 
Amplified cDNA encoding STAT1 and the plasmid pET-22b were cut with the same 
restriction enzymes Nde I and Sal I (Jena Bioscience) so that to create complementary 
sticky ends which facilitate the subsequent ligation. The reactions were incubated at 
37°C for 3 hours. Then the enzymes were inactivated by incubation at 65°C for 20 
minutes. 
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A Calf Intestinal Alkaline Phosphatase (CIAP, Sigma-Aldrich®, 1U/µl) was added to 
the pET-22b plasmid, after digestion; the reaction took place for 1 hour at 37°C. 
CIAP treatment prevents self-ligation of the vector because removes the 5 phosphate 
from both termini of the linear vector. 
The digested plasmid and insert were isolated by agarose electrophoresis and purified 
by the QUIAEX®II Gel Extraction Kit (QIAGEN).   
 Ligation of the STAT1 insert and of the  pET-22b plasmid 
In order to improve the efficiency of the ligation, a proper insert/vector ratio is 
required. To this aim, we determined insert and vector concentration by estimating 
DNA amount by agarose gel electrophoresis. 
The ratio of STAT1 insert to destination plasmid was 5:1, it was calculated by using 
the equation: 
Ng insert= 5*(kb insert)*(ng plasmid)/(kb plasmid);  
T4 DNA ligase (Promega) was used for the ligase reaction, and the mixture was 
incubated overnight at 4°C.  
 Preparation of competent E. coli cells using CaCl2 
The product of the ligase reaction was then introduced into the E. coli XL1-blue 
strain by a reaction of transformation. 
One colony of E.coli cells, grown on an LB agar plate at 37°C overnight, was placed 
in 5 ml LB media and was allowed to grow overnight at 37°C under agitation. The 5 
ml of overnight culture were transferred into 200 ml of LB media in a flask and the 
cells were allowed to grow under agitation at 37°C until the OD600 of  0.4-0.6. Cells 
were transferred into 4 polypropylene falcon tubes (50 ml) and centrifuged at 4°C for 
10 minutes at 3000 x g. Media was poured off and cells were resuspended in 25 ml of 
cold 50 mM CaCl2 , previously filtered and sterilized through a 0.22 µm filter, and 
were incubated on ice for 30 minutes. Cells were centrifugated at 4°C for 10 minutes 
at 3000 x g. Supernatant was poured and cells were resuspended (by pipetting) in 5 
ml cold 50 mM CaCl2 containing 15% glycerol. 300 µl were transferred into 
sterilized Eppendorf tubes (1.5 ml) placed on ice. The cells were frozen in liquid 
nitrogen and stored at -80
o
C. These cells could be used for transformation . 
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 Transformation of competent E. coli cells by heat shock to amplify the 
product plasmid 
XL1-blue strain of E. coli was used to amplify the plasmid. The competent cells were 
removed from -80°C storage and placed on ice. As the cells were thawed, 150 µl of 
these cells were transferred into Eppendorf tube (1.5 ml) and 30 ng of DNA obtained 
by ligation with the plasmid was added; tubes were kept on ice for 30 minutes. Then, 
tubes with DNA and bacteria were placed into a water bath at 42°C for 45 seconds 
and subsequently on ice for 5 minutes. 200 µl of LB was added and tubes were 
incubate for 45 minutes in agitation at 37°C. The resulting cultures were spread on 
LB agar with ampicillin (100 µg/ml) and were allowed to grow overnight at 37°C. 
 PCR Screening of Transformant Colonies 
After obtaining colonies from a transformation reaction, some colonies were 
resuspended in 5 µl of water, a PCR reaction was carried out using Taq polymerase 
and the same reaction mix and program used for amplification of insert. The PCR 
samples and 1kb molecular weight marker were run on 0.8% agarose gel and 
visualized at UV lamp. 
Since the PCR colonies might give “false-positives”, some single transformant 
colonies of XL1-Blue were inoculated with 3 ml of LB, containing ampicillin, and 
incubated overnight at 37°C. The plasmid DNA was extract by GenElute™ Plasmid 
Miniprep Kit (Sigma-Aldrich) and checked by sequencing (BMR genomics). 
 Expression of the STAT1 protein in the BL21 strain of E.coli 
Cells of the BL21 strain of E.coli were transformed by heat shock, as described 
before, with 50 ng of the pET22b vector containg the insert encoding from STAT1.  
A colony of the transformed cells was placed in 3 ml LB media with ampicillin and 
allowed to grow for 6 hours at 37°C under agitation. Then, the 3 ml culture was put in 
20 ml of LB with ampicillin and allowed to grow overnight at 37°C in agitation. The 
overnight culture was transferred into 1 L LB media with antibiotic in a flask, the 
cells were allowed to grow at 37°C under agitation until the OD600 reached a value of 
0.6-0.8, which represent the exponential growth phase. At this point IPTG (0.5 mM) 
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was added to the culture medium and cells were allowed to grow overnight at 20°C 
under agitation. 
Before the induction with IPTG and after nearly 16 hours of induction, 1 ml of 
culture was  centrifuged at 12000 x g and suspended in Sample-Buffer. The induction 
was verified by SDS-PAGE and by Western Blot using a specific antibody against 
STAT1 (Santa Cruz Biotechnology). 
The pellet of 1 L culture was resuspended in Tris 20 mM pH 7.5, NaCl 0.5 M, 
imidazole 10 mM, β-Mercaptoethanol 5 mM and PMSF (phenylmethylsulfonyl 
fluoride) 0.2 M. Cells were sonicated, frozen in liquid nitrogen and stored at -80
o
C 
until use. 
 STAT1 protein purification 
STAT1 protein was purified by affinity chromatography, that is based on the specific 
and reversible interaction between a particular protein to be purified and a ligand 
previously immobilized on a stationary phase. The process can be thought as an 
entrapment, because the target molecule with a particular property is trapped on a 
solid or stationary phase, while others molecules in solution are not retained.  
Recombinant proteins may be easily purified by immobilized metal ion 
chromatography (IMAC). In this work HisTrap FF crude (GE Healthcare) column 
was used. It is prepacked with NiSepharose™ resin, which consists of highly cross-
linked agarose beds with an immobilized chelating group. The column is precharged 
with Ni
+
 ions that are able to form a complex with this residues, thus Ni
+
 ions 
selectively bind those proteins that have this residues exposed on their surface.  
The E. coli lysate was thawed at 37°C in a water bath, added of Leupeptin and 
Pepstatin 100 µg/l and centrifuged 12000 x g at 4°C for 30 minutes. The supernatant 
was filtered with a gauze and loaded on the column by FPLC AKTA (GE Healthcare) 
synstem. 
The protein was eluted by adding a competitive molecule, i.e. imidazole. A linear 
gradient of imidazole (10 mM – 500 mM) was applied in Tris-HCl 20 mM pH7.5, 
NaCl 0.5 M. 
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The different eluted fractions and the unbound fraction were analyzed by SDS-
PAGE. 
The gel was then stained by a staining solution (25% v/v ethanol; 10% v/v glacial 
acetic acid; 0.15% p/v comassie brilliant blue) for 30 minutes and then was bleached 
a by destaining solution (25% v/v ethanol; 10% v/v glacial acetic acid). 
3.10 Site-directed mutagenesis of STAT1 protein 
Site-directed mutagenesis was performed using QuikChange®II Site-Directed 
Mutagenesis Kit (Stratagene) which allows to generate mutants by a rapid three-steps 
procedure (Fig. 11).  
Amplification is a PCR reaction which utilizes the supercoiled double-stranded DNA 
(pET-22b vector) containing the cDNA encoding for STAT1 as template, and two 
synthetic oligonucleotide primers, each complementary to opposite strands of the 
vector and containing the desired mutation. 
The mutagenic oligonucleotide primers used to consent the Q518A and the H568A 
variants were the following: 
Q518A-FOR:CTCAATGTGGACGCGCTGAACATGTTG 
Q518A-REV:CAACATGTTCAGCGCGTCCACATTGAG 
H568A-FOR:CTCATTAAAAAAGCGCTGCTCCCTCTC     
H568A-REV:GAGAGGGAGCAGCGCTTTTTTAATGAG 
The site-directed mutagenesis was performed using PfuUltra ™ high-fidelity DNA 
polymerase.  
Cycling parameters for site-directed mutagenesis were: 
1. 5 minutes at 95°C for initial denaturation 
2. 30 seconds at 95°C for denaturation 
3. 60 seconds at 55°C for annealing 
4. 10 minutes at 68°C for extension  
5. 10 minutes at 68°C for final extension  
The steps from 2 to 4 were repeated 16 times in an Eppendorf® termocycler. 
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The amplification products were digested with Dpn I enzyme for 3 hours at 37°C. 
Dpn I is a specific endonuclease which digests the parental (non-mutated), 
methylated dsDNA. A part of the products was pipetted in a 0.8% agarose gel to 
confirm the amplicon presence. 
XL1-Blue competent cells were then transformed with 5 µl of the digested DNA, as 
previously described, and the STAT1 sequence was sequenced to check the presence 
of desired mutation.  
 
 
Figure 11: Overview of QuikChange II site-directed mutagenesis method 
 
 
3.11 Surface Plasmon Resonance (SPR) analysis 
Study of the interaction between STAT1 protein and catechins were carried out by 
Surface Plasmon Resonance (SPR) analysis using “BIAcore 2000 biosensor system” 
(BIAcore inc., Piscataway, NJ, USA). 
SPR is an ”in vitro” technique based on an optical phenomenon, and can 
simultaneously detect interactions not only between proteins but also between 
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proteins and small molecules. BIAcore instruments consist of sensing optics, an 
automated sample delivery system, and a computer for instrument control, data 
collection and data processing. Furthermore, careful data analysis lead to evaluate 
kinetics parameters of the interaction.  
Experiments were performed on disposable sensor chip CM5 (carboxylated dextran 
chip). The chip has two flow channel, in one flow channel STAT1 protein (the 
ligand), 0.05 mg/ml in sodium acetate buffer 10 mM pH 4.0, was immobilized by an 
amine coupling reaction kit (BIAcore Inc., Uppsala, Sweden) according to 
manufacturer’s instructions. First a EDC/NHS solution (freshly mixed 0.2 M N-ethyl-
N9-dimethylaminopropylcarbodiimide and 50 mM N-hydroxysuccinimide) was 
injected for 7 minutes to activate the surface, and next STAT1 was injected, followed 
by 1 M ethanolamine at pH 8.5 for 7 minutes to stop further binding. The other flow 
cell without STAT1 was used as control. 
After activation and immobilization of STAT1, each catechin (the analyte) in running 
buffer (HBS-EP buffer, BIAcore) was injected into the flow cell containing 
immobilized STAT1, appropriate concentration ranges of compounds were 
determined from anticipated preliminary experiments. Analysis were performed with 
EGCG, GCG, compounds 1, 2, 3, 7, 8 and 9 at concentrations of 0, 0.2 - 50 µM, and 
with compounds 4, 5, 6, 10 to 15 at concentrations of 5 to 200 µM in the final volume 
50 µL. Elution rate was 30 µLmin
-1
 for each experiment. At operative temperature 
(25°C) one analytical cycle consisted of 6 minutes of buffer flow, followed by 6 
minutes of test compound at reported concentration in HBS-EP buffer and 8 minutes 
of buffer flow to follow the dissociation phase. Before the successive cycle the 
surfaces were regenerated with 30 seconds injections of 5 mM NaOH followed by 
HBS-EP buffer for 6 minutes. Sensograms expressed in resonance unit (RU) for each 
compound were analyzed with BIAevaluation software and BIAsimulation software 
(BIAcore Inc.). 
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3.12 Computer modelling 
The molecular modelling was performed in collaboration with prof. Perahia group,  
“Laboratoire de Modelization et Ingenierie des Proteines” (University of Paris-sud,  
Orsay France). 
The search of putative interaction sites of catechins with STAT1 was carried out 
using Q-sitefinder
 
(http://www.bioinformatics.leeds.ac.uk/qsitefinder/) on the X-ray 
structure of STAT1 (pdb entry 1yvl.pdb Laurie, A.T. and Jackson, R.M. 2005). 
Docking simulations were carried out using Autodock v.4
 
(Morris G.M. 1998) which 
was recently reported as part of the most accurate softwares for that matter 
(Bursulaya B.D et al., 2003; Jenwitheesuk E. et al. 2003). This docking software was 
used with full flexibility of the ligands but with limited protein flexibility. The initial 
geometry of the ligands was obtained by minimization with the semi empirical 
method AM1 by using Gaussian03 (Frisch M. J. et al. 1998; Pettersen E. F. et al. 
2004; Pedretti A. 2004) program in vacuum. ADTOOLS, the graphical interface of 
Autodock was used for adding the polar hydrogens for docking calculations and for 
assigning the atomic charges of the protein.  
Calculations with Autodock were performed using a particularly accurate procedure 
using the Lamarckian algorithm with a population size of 100, a number of energy 
evaluations of 2.0 x 10
6
, a generation number of 27,000, a mutation and crossover 
rates of 0.02 and 0.8 respectively. The energies were evaluated by using atomic 
affinity potentials for each atom type of the ligand calculated by Autogrid v3.0.5. 
Furthermore, the number of runs was set to 100 to explore a large number of poses of 
the highest affinity and the Solis and Wets algorithm was used to relax the best 10 % 
of the obtained conformations.  
3.13 STAT1/JAK2 Kinase assay 
JAK2 kinase causes STAT1 phosphorylation in Tyr701 and its activation. A kinase 
semiquantitative assay was improved to assess the change in wild-type and mutated 
STAT1 phosphorylation following catechin treatment. It was performed under 
Materials and Methods 
50 
 
agitation at 37°C in 30 µl volume composed of reaction buffer (Tris-HCl 20 mM pH 
7.5; ATP 100 µM; MgCl2 50 mM), STAT1 (recombinant purified protein) and JAK2 
(recombinant enzyme, Millipore) at different concentrations  (STAT1 500 ng - 5 µg; 
JAK2 3 ng – 300 ng). The reaction was stopped by adding 10 µl of Sample Buffer 
4X, proteins were denatured at 95°C for 5 minutes, were fractionated by 
electrophoresis on 10% SDS-PAGE and analyzed by Western Blot using antibodies 
anti-phosphoSTAT1 Tyr701 (Cell Signaling Technology, MA, USA) and anti-
phosphoJAK2 Tyr1008 (Millipore, Bedford, MA, USA) diluted 1:700 and 1:500, 
respectively, in blocking solution. To set up the kinase assay, different reaction times 
(from 2 to 20 minutes) were performed. 
Once the better condition for the kinase activity was detected, catechins were pre-
incubated at different times (10 and 30 minutes) with STAT1 recombinant protein to 
identify the optimal interaction time. The best condition for JAK2 Kinase assay was: 
30 minutes of pre-incubation of the catechins at 37°C under agitation with wild-type 
and mutated STAT1 (0,16µg/µl); 5 minutes of kinase reaction with JAK2 (0,16ng/µl) 
at 37°C under agitation.  
3.14  Statistic 
When necessary data were expressed as means ± S.D. of at least three independent 
experiments and statistical analysis for single comparison was performed using 
Student’s t-test. The criterion for statistical significance was  P < 0.01. 
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4. Results 
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4.1 Synthetic Catechins 
A number of catechins were synthesized by the group of prof. Sergio Romeo, Faculty 
of Pharmacy, University of Milan.  
As already mentioned, these compounds were analogous to GCG, diastereomer of 
EGCG, because GCG was more stable and easier to synthesize than EGCG. To study 
the importance of rings A, B, D and their hydroxyl groups on the IFN-elicited 
STAT1 activation, new catechins were synthesized with fewer hydroxyl substituents 
than GCG in rings A, B and D (Fig. 12 and Table 2), in order to analyze the minimal 
necessary and sufficient structure for anti-STAT1 activity.  
As shown in table 2, compound 1 is the racemic mixture in 3 of GCG  (2S, 3R; 2S, 
3S) and was considered as the reference compound in the different experiments. 
Compounds 2 and 3 present less hydroxyl groups in ring A, while compounds 4, 5 
and 6 have reduction of hydroxyls in ring B, changes in ring D can be noticed in 
compounds 7, 8, 9 and 10. Finally compound 11 to 15 have less hydroxyl groups in 
more than one ring simultaneously. 
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COMPOSTO R1 R2 R3 R4 R5 R6 R7 R8
1 OH OH OH OH OH OH OH OH
2 OH H OH OH OH OH OH OH
3 H H OH OH OH OH OH OH
4 OH OH H OH OH OH OH OH
5 OH OH H OH H OH OH OH
6 OH OH H H H OH OH OH
7 OH OH OH OH OH H OH OH
8 OH OH OH OH OH OH H OH
9 OH OH OH OH OH H OH H
10 OH OH OH OH OH H H H
11 OH H OH H OH OH OH OH
12 OH OH H OH OH OH H OH
13 OH H OH H H OH OH OH
14 H H H H H OH OH OH
15 H H H H H H H H  
Figure 12: General structure of catechin gallate 
 
 
4.2 Structural features of anti-STAT1 synthetic catechins 
4.2.1 DNA binding activity 
 
Previously study reported that 20 µM EGCG reduced completely STAT1 DNA-
binding activity in MDA MB 231 cells treated with IFN (Menegazzi M. et al., 2001). 
To examine the importance of stereochemistry in this action, GCG was further tested 
for its capacity to reduce STAT1 DNA-binding activity. EMSA showed that GCG 
exerted an inhibitory action in the same content to EGCG (Fig. 13), indicating that 
the two stereoisomers cannot be distinguished regarding their capacity to inhibit 
STAT1 DNA-binding activity. In order to envisage the structural features involved in 
this activity, a structure activity relationship study was performed using MDA MB 
231 cell line. The synthetic catechins at different concentrations were administered to 
the cells one hour before the cell stimulation with IFN (30 ng/ml) for 1 hour. As 
shown in figure 14, at 20 µM compounds 1 and 2 showed a strongest inhibitory 
action, reducing STAT1 DNA-binding activity to less than 30 % of that of induced 
cells. The estimated IC50 was around 12 µM for compound 1 and 17 µM for 
Table 2: Synthetic Catechins 
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compound 2. At the same concentration (20 µM) compound 3 reduced STAT1 DNA-
binding activity to 70 % of that of induced cells with estimated IC50 to be around 28 
µM. Compounds 7, 8 and 9 reduced STAT1 DNA-binding activity, with estimated 
IC50 to be around 33, 37, 31 µM respectively. All other synthetic catechins were 
inactive in reducing STAT1 DNA-binding activity (Fig. 14 and data not shown).  
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Compounds −     −    EGCG GCG   1     1
 µM −     −     20    40    20    40   20   40
IFN −       
STAT1
 
Figure 13: Effects of EGCG, GCG and compound 1 on STAT1 activation. 
Figure 13 shows DNA binding activity of STAT1 in MDA MB 231 cell line untreated or induced by IFN in the 
presence or absence of different concentrations µM of EGCG, GCG and compound 1.   Cell nuclear extracts (10 
g) were incubated with a 32P-labeled double-stranded oligonucleotide containing binding sequence for STAT1 
and separated by nondenaturing PAGE. The specificity of the retarded bands was demonstrated by competition 
with 100-fold excess of specific unlabeled oligonucleotide (not shown). The gel is representative of three separate 
experiments. 
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Figure 14:   Effect of synthetic catechins on STAT1 activation.  
Figure 14 shows DNA binding activity of STAT1 in MDA MB 231 cell line untreated or induced by IFN in the 
presence or absence of different concentrations µM of synthetic catechins (each compound is identified by a 
number as shown in table 3). Cell nuclear extracts (10 g) were incubated with a 32P-labeled double-stranded 
oligonucleotide containing binding sequence for STAT1 and separated by nondenaturing PAGE. The specificity 
of the retarded bands was demonstrated by competition with 100-fold excess of specific unlabeled oligonucleotide 
(not shown). Each gel is representative of five separate experiments. 
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4.2.2 STAT1 phosphorylation 
 
In the IFN/JAK/STAT1 pathway, STAT1 activation occurs after the phosphorylation 
of STAT1 proteins by JAKs. Phosphorylation in Tyr701 of the two STAT1 
monomers is the necessary and sufficient condition for dimerization (Schindler C. et 
al., 1992; Shuai K. et al., 1992), nuclear translocation and DNA binding. Although 
phosphorylation in Ser727 of STAT1 is not necessary to DNA binding of this 
transcription factor, however, it is very important for a maximal transcriptional 
activity. So, to clarify the anti-STAT1 activity of these compounds, western blot 
analysis were performed in total cellular extracts, using two rabbit polyclonal 
antibodies that recognized STAT1 phosphorylated in Tyr701 and Ser 727, 
respectively. 
The western blot showed  high level of phosphorylated Tyr701 STAT1 1 hours after 
the induction with IFN (30 ng/ml) (Fig. 15). The pre-treatment of active synthetic 
catechins (compounds 1, 2, 3, 7, 8 and 9) reduced Tyr701 phosphorylation, in 
particular compounds 1, 2 and 7 acting stronger than compounds 3, 8 and 9 (Fig. 15). 
GCG and compound 1, which is the racemic form of GCG, had similar activity 
(Fig.15). 
To test the ability of these molecules to inhibits the phosphorylation in Ser727 of 
STAT1, a second blot was  hybridized with anti-posphoSTAT1(Ser727) antibody, as 
shown in figure 15. The control cells show slight phosphorylation, compounds 1, 2 
and 9, and to lesser content compounds 3, 7 and 8 compared to the induced sample, 
inhibited this phosphorylation. 
No significant changes in the amount of total STAT1 protein was observed (Fig. 15). 
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Figure 15: Effect of synthetic catechins on Tyr701 and Ser727 phosphorylation of STAT1 in MDA MB 231 
cells treated with IFN. 
50 µg of total extracts of cells treated as in figure 14 were separated by denaturing SDS-PAGE, electroblotted 
onto PVDF membrane and probed with an antibody recognized phosphorylated STAT1 in Tyr701, and Ser727. 
Top panel shows immunoblot of STAT1 phosphotylated in Tyr701, the antiphosphoSTAT1 Tyr701 antibody was 
diluted 1:700 in BSA 5%; in the central panel the same samples are probed with antiphosphoSTAT1 Ser727 
(lowest band), the antibody was diluted 1:300 in BSA 5%. Lower panel shows the same samples and blot stripped 
and reprobed with an antibody recognizing STAT1 total protein, diluted 1:1000 in milk 5%. Data shown are 
representative of three independent experiments. Note that there are two forms of STAT1: STAT1 α and STAT1 
β. The first contains two phosphorylation sites at Tyr701 and, in its carboxyl-terminal domain, Ser727. STAT1 β 
is an alternatively spliced version of STAT1 that lacks 38 carboxyl-terminal residues, including Ser727. The blots 
for STAT1 or phosphoSTAT1 Tyr701 detect the doublet of STAT1 α (upper band) and β (lower band), whereas 
antiphosphoSer727 detects the single STAT1 α band; the upper band of this blot is a non specific  band (N.S.).      
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4.2.3 Modulation of gene expression 
 
Since IFN/JAK/STAT1 pathway elicits the expression of different STAT1 
dependent genes, the ability of the anti-STAT1 synthetic catechins to inhibit the 
expression of two genes was studied. The genes considered in this work encode for 
inducible Nitric Oxide Synthase (iNOS) and for Major Histocompatibility Complex 
Class II DR alpha (MHC II DRA). While the expression of MCH II genes is induced 
by IFN alone, in human cells, other different cytokines are also required to have a 
full iNOS induction. In this work MDA MB 231 cells were pre-treated with synthetic 
catechins for one hour, then they were induced only with IFN (30 ng/ml) for 30 
hours, to exclude the involvement of NF-κB transcription factor. Total RNA were 
purified from cells and the amount of specific mRNAs was quantified with Real-
Time PCR as described in Materials and Methods and shown in the histograms (Fig. 
16 and 17).  
Although IFN alone elicited low level of iNOS gene induction in MDA MB 231 cell 
line (about two fold), figure 16 shows that only compounds 1, 2, 3, 7, 8 and 9 were 
able to inhibit iNOS expression at different manner. The amount of MCH II DRA 
mRNA levels are shown in figure 17. This histogram shows that: 1. treatment with 
IFN alone gives a very good gene induction (10 fold) in comparison to the control 
sample; 2. compounds 1, 2, 3, 7, 8 and 9 are able to completely inhibit the MCH II 
DRA gene expression, in fact they all have almost the same value of mRNA level of 
control sample. All other synthetic catechins are inactive (data not shown). Only a 
trend of reduction of MCH II DRA gene expression is shown after pre-treatments 
with compounds 5 and 10; this in not statistically significant for P < 0,01.   
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Figure 16: Inhibition of iNOS gene expression after IFN induction.  
Cells MDA MB 231 were pre-treated with different catechins for 1 hour and induced with IFN (30ng/µl) for  30 
hours; total RNA was extracted, purified and quantified as described in materials and methods. The histogram 
shows iNOS mRNA levels quantified by Real-Time PCR assay. Compounds 1, 2, 3, 7, 8 and 9 are able to inhibit 
iNOS gene expression, while compounds 5 and 10 are not. Values are averages of three independent experiments 
± S. D. *P<0.01 vs. IFN treated cells.  
 
 
 
 
 
0
20
40
60
80
100
120
A
rb
it
ra
ry
 u
n
it
s
*
*
*
*
*
*
**
Results 
61 
 
 
Figure 17: Inhibition of MCH II DRA gene expression after IFN induction.  
Cells MDA MB 231 were pre-treated with different catechins for 1 hour and induced with IFN (30ng/µl) for 30 
hours; total RNA was extracted, purified and quantified as described in materials and methods. The histogram 
shows MCH II DRA mRNA levels quantified by Real-Time PCR assay. Compounds 1, 2, 3, 7, 8 and 9 are able to 
inhibit MCH II DRA gene expression, while compounds 5 and 10 are not. Values are averages of three 
independent experiments ± S. D. *P<0.01 vs. IFN treated cells.  
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4.3 Direct interaction between anti-STAT1 catechins and  STAT1 
protein   
4.3.1 Surface Plasmon Resonance analysis  
 
Okabe et al. study, using radiolabeled catechins, showed that natural catechins are 
able to cross plasmatic membrane and enter into the cells (Okabe S. et al., 1997). So 
the possible target of the anti-STAT1 molecular mechanism should be an intracellular 
target and we verified in this work whether catechins interact directly with STAT1 
protein itself.  
In order to evaluate this hypothesis Surface Plasmon Resonance (SPR) analysis were 
performed. First STAT1 protein was cloned in a vector suitable for expression in 
bacteria (pET22b), expressed in BL21 strain of E.coli and purified by affinity 
chromatography, as described in Materials and Methods. Then STAT1 was 
immobilized on sensor chip and the interaction with catechins was analyzed by 
BIAcore instrument.     
Analysis of sensograms by “BIAevaluation software” and “BIAsimulation software” 
provided ka and kd values and dissociation constant (KD) was calculated and showed 
in Table 3. Figure 18 and 19 show some examples of interaction or no interaction 
between STAT1 protein and some compounds. First part of response curves (rising 
graph) represents the association phase between STAT1 and the considered 
compounds, and allows to measure the association rate constant (ka); the second part 
of responsive curves (descending graph) represents the dissociation phase and gives 
the dissociation rate constant (kd). In the better sensograms there is also an 
equilibrium phase between association and dissociation, which represents the steady 
state and allows to calculate the dissociation constant (KD = kd /ka). 
As shown in figures 18 and 19, sensograms clearly indicated that not only EGCG and 
GCG but also all catechins that reduced STAT1 activity (compounds 1, 2, 3, 7, 8 and 
9) were able, in different ways, to interact directly with STAT1 protein.  
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With a detailed analysis of sensograms obtained with catechins that exert a stronger 
inhibitory action on STAT1 activity (GCG, EGCG, compounds 1, 2 and 3), two 
dissociation constants could be calculate: KD1 (nM) which indicated high affinity of 
STAT1 binding and KD2 (µM) at low affinity. To explain these data, we suppose the 
presence of two putative interacting sites for the catechins on STAT1 protein with 
different affinity constants. The KD1 values estimated for GCG (16.9 nM), EGCG (23 
nM), compound 1 (37.3 nM) and compound 2 (27,6 nM) indicated that the interaction 
between STAT1 and these compounds might be very tight at one of putative 
interaction site (Table 3). Interaction between STAT1 and compound 3 (534 nM) also 
appeared strong. Compounds 7, 8 and 9, with less anti-STAT1 activity, showed mild 
STAT1 interaction. Indeed, analysis of their sensograms (Fig. 18) determined only 
one KD value (11.8 µM, 2.42 µM, 7.36 µM respectively) (Table 3). Other catechins 
such as compounds 5, 6, 11, 12 and 14 with high KD value, varying from 50 to 2 x 
10
2
 µM, showed very weak interaction (Table 3). Compounds 4, 10, 13 and 15 did 
not produce analysable sensograms suggesting that there is not at all STAT1 
interaction with these catechins (Fig. 19).  
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Figure 18: 
Examples of sensograms of anti-STAT1 catechins. 
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Figure 19: 
Examples of sensograms indicating very weak or no interaction between STAT1 and compounds 
5 and 10. 
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Compounds  K
D1
 (nM) K
D2
 (µM) 
EGCG  23  2.55  
GCG  16.9  2.19  
1  37.3  3.11  
2  27.6  15.2  
3  534  7.85  
K
D
 (µM) 
4  -   
5  7.30 x 10
2
  
6  7.11 x 10
2
  
7  11.8 
8  2.42 
9  7.36 
10  -  
11  4.83 x 10
2
  
12  52.3 x 10
2
  
13  -  
14  2.54 x 10
2
  
15  -  
  
 
 
Table 3:  
Estimated values of the dissociation constants (KD = kd /ka) of the catechins tested. 
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4.3.2 Computer Modelling Studies 
 
The possible interaction between catechins and STAT1 was analyzed by molecular 
modelling studies, in order to determine possible catechin binding sites on the STAT1 
structure. This analysis was performed in collaboration with Prof. Perahia of the 
“Laboratoire de modelization et ingenierie des proteins” of the University Paris-sud.  
Starting from the X-ray structure of STAT1 (pdb entry 1yvl) specific different 
software were applied which allowed the identification of five major putative binding 
sites for GCG (Fig. 20). Two of them were located at the interface between the linker 
and SH2 domains (sites 1 and 2). The three remaining sites have a location closest to 
the region of STAT1 that interacts with DNA: one is located in the DNA-binding 
domain (site 3) and the two others are located at the interface between the DNA-
binding domain and the linker domain (sites 4 and 5). The putative sites 3, 4 and 5 
were ignored in this work since the free energy of the most stable docked  
orientations of the catechin in these sites was significantly higher than that of sites 1 
and 2 (site 1: -10.90; site 2: -10.84; site 3: -8.96; site 4: -7.72; site 5: -7.65 kcal/mol). 
Furthermore, our data have shown that EGCG and GCG were not able to block the 
STAT1-DNA-binding in EMSA assay when they were added directly to the nuclear 
extracts containing STAT1 already activated proteins in the incubation mixture (data 
not shown). This could indicate either that catechins do not interact with the STAT1 
in its DNA-binding domain or that the two catechins are not able to bind to already 
phosphorylated STAT1 proteins.  
In order to better understand the nature of catechins-STAT1 interaction at the 
molecular level, docking calculations were performed for all the tested catechins, as 
reported in the Materials and Methods section. These simulations predict good 
binding affinities for anti-STAT1 compounds both at site 1 and 2. The detailed 
analysis of the best predicted orientations of the ligands in the different cavities 
shows that the hydroxyl groups of ring B seem to be very important for stabilizing 
catechins-STAT1 complexes. These groups were oriented towards the interior of the 
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cavity in both sites (Fig. 21) and seem to interact with residues Arg512, Gly513 and 
Gln518 on site 1 (Fig. 22 a), and with His568, Lys566 and Leu570 on site 2 (Fig. 22 
c). However non-anti-STAT1 ligands, with fewer hydroxyls in ring B than GCG 
(compound 5)  or without hydroxyls in ring D (compound 10), were oriented with the 
ring B towards the exterior of the cavity, interacting with other residues as shown in 
figures 22 b and d that represents the best pose of compound 5 in the two different 
sites. Thus on the basis of these analyses, the tested ligands could be divided into two 
subgroups, one of compounds that show good affinities of STAT1 binding (EGCG, 
GCG, compounds 1, 2, 3, 7, 8 and 9) and the other that show less affinities 
(compound 4, 5, 6 and 10 to 15).  
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Figure 20:  Location of STAT1 – GCG potential binding sites. Schematic view of STAT1 represented in 
cartoon without the N-domain (structure pdb reference 1YVL); the different domains as well as the five binding 
sites are indicated. 
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Figure  21:  Surface representation of the two binding sites colored by the element type; oxygen (red), 
nitrogen (blue), carbon (white) and sulphur (yellow). GCG is represented in stick and ball. 
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Figure 22:  Representations of the best Autodock pose of GCG and compound 5 in the two binding sites. 
The ligand is in balls and sticks, interacting residues are in sticks and the secondary structure is in cartoon. a) 
GCG in site 1, b) compound 5 in site1, c) GCG in site 2 and d) compound 5 in site 2.     
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4.3.3 Site-directed mutagenesis  
 
Molecular modelling studies have shown that most of the ligands considered could 
interact with STAT1 protein by their hydroxyls groups on the B and D rings. In site 1 
anti-STAT1 catechins seem to bind to the side chains of Arg512, Gly513, Asp517, 
Gln518, Asp575 and Cys577; in site 2 catechins seem to bind to the main peptide 
chain of Lys566, Leu570, Lys679 and Tyr680, as well as to the side chain of His568. 
Moreover the latter amino acid seems to bind to another α chain domain, probably by 
interacting with Leu639. In this way the two chain domains could form a pocket for 
ligand insertion.  
To test the possibility that Gln518 and His568 could be important for the catechin-
STAT1 interaction on site 1 and 2 respectively, site-directed mutagenesis experiments 
were performed. Both Gln518 located in site 1 and His568 in site 2 were replaced 
with Ala (QA and HA, respectively) and the catechins affinities for the mutant form 
of STAT1 were analyzed by Surface Plasmon Resonance.  
The obtained dissociation constants (KD) are reported in Table 4 and indicate that the 
replacement of Gln518 of STAT1 with Ala (QA) produce two dissociation constants. 
For each catechin the KD1 (nM) value is not modified, while KD2 (µM) value is higher 
than that of STAT1 wild-type. This data strongly suggest that Gln518 could take part 
of site 1 and that this site is identified as the less affinity site for the catechins 
binding. 
On the other hand, when His568 is replaced by Ala (HA), KD1 (nM) disappears while 
KD2 (µM) values increase with respect to the KD2 values of STAT1 wild type protein. 
On the basis of these results it is possible to conclude that His568 take part of site 2, 
which is characterized by an higher affinity with respect to site 1 for the ligands 
considered. Moreover our data demonstrate that His568 is essential for anti-STAT1 
catechins binding. 
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Compounds STAT 1 WT STAT 1 QA STAT 1 HA 
 KD1(nM) KD2(µM) KD1(nM) KD2(µM) KD1(nM) KD2(µM) 
GCG 16.9 2.19 28.6 240 - 22.4 
2 27.6 15.2 14.2 68.4 - 99 
3 534 7.85 607 137 - 69.4 
 
Table 4 : Estimated values of the dissociation costants of the catechins tested with mutant STAT1 in Gln518 
(QA) and in His568 (HA), in relation to STAT1 protein wild type (WT). 
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4.3.4 JAK2 kinase assay 
 
The first step of the activation of STAT1 protein is the phosphorylation at Tyr701; 
our data demonstrated that some catechins provoke a reduction in Tyr701 
phosphorylation. To demonstrate that  the direct interaction between active catechins 
and STAT1 protein could prevent Tyr701 phosphotylation, a kinase assay was 
performed using JAK2 recombinant enzyme since JAK2 is the protein kinase 
responsible to phosphorylation of STAT1 in Tyr701.  
As reported in Materials and Methods section, in the reaction buffer STAT1 
recombinant protein (0,16 µg/µl) was incubated with Jak2 recombinant protein (0,16 
ng/µl) for 5 minutes after 30 minutes of  the pre-incubation time with the catechins. 
Figure 23 shows the ability of anti-STAT1 catechins, as GCG and compound 2, to 
reduce the STAT1 phosphorylation in a dose-dependent manner. While, the inability 
of inactive compounds to prevent STAT1 phosphorylation was showed in figure 24 
(compounds 5 and 10). In addition all catechins were ineffective to inhibit the 
phosphorylation status of activated JAK2. 
The kinase assay with mutant STAT1 in His568Ala (Fig. 25) demonstrates that active 
compounds are unable to reduce the STAT1 Tyr701 phosphorylation, suggesting that 
the STAT1-catechins interaction on the site 2 is important to preserve the inhibitory 
action on STAT1 Tyrosine phosphorylation.  
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Figure 23: Kinase assay of active compounds. GCG and compound 2 were pre-incubated for 30 minutes at 
different doses with STAT1 recombinant protein. JAK2 recombinant protein was added for 5 minutes to the 
reaction mixture thus the samples were analyzed by western blot with anti-phosphoSTAT1 (Tyr701) and anti-
phosphoJAK2 (Tyr1007) antibodies. Blots were stripped and reprobed with antibodies recognizing STAT1 or 
JAK2 proteins. Lane 1 shows reaction between STAT1 and JAK2 in reaction buffer; lane 7 shows STAT1 protein 
alone. Data shown are representative of three independent experiments.  
  
  
 
 
 
 
 
 
 
    GCG          −         5          25      50           −         −           − 
   
Compound 2          −          −          −          −         25       50         − 
Lane            1         2            3          4           5          6         7  
pSTAT1 
STAT1 
pJAK2 
JAK2 
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Figure 24: Kinase assay of non active compounds. The compounds 5 and 10 were pre-incubated at different 
concentration for 30 minutes with STAT1 recombinant protein. JAK2 recombinant protein was added for 5 
minutes to the reaction mixture, thus the samples were analyzed by western blot with anti-phosphoSTAT1 
(Tyr701) and anti-phosphoJAK2 (Tyr1007) antibodies. Blots were stripped and reprobed with antibodies 
recognizing STAT1 or JAK2 proteins. Lane 1 shows STAT1 protein alone; lane 5 shows reaction between STAT1 
with JAK2 in reaction buffer. Data shown are representative of three different experiments. 
 
 
 
                             
 
Figure 25: Kinase assay with mutated STAT1 recombinant protein (H568A). GCG and compound 2 were pre-
incubated for 30 minutes at different dose with STAT1 recombinant protein mutated in His568 with Ala. JAK2 
recombinant protein was added for 5 minutes to reaction mixture, thus samples were analyzed by western blot 
with anti-phosphoSTAT1 (Tyr701) antibody. Lane 1 shows mutated STAT1 protein alone; lane 2 shows reaction 
between mutated STAT1 and JAK2 in reaction buffer. Data shown are representative of three independent 
experiments. 
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5. Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
78 
 
 
An increasing body of evidence indicates beneficial actions of green tea drinking that 
might be extended to a number of pathologies correlated to inflammation (Choi Y. B. 
et al., 2004; Crespy V. and Williamson G., 2004; Dona M. et al., 2003; Kakuda T., 
2002). Previous work in our laboratory demonstrated that EGCG efficiently inhibits 
interferon (IFN)-elicited phosphorylation of tyrosine residue 701 and DNA-binding 
activity of STAT1 in different human carcinoma-derived cell lines (Menegazzi M. et 
al., 2001). STAT1 almost exclusively mediates the action of IFN, playing a pivotal 
role at the early phase of inflammation in regulating the expression of a number of 
inflammation related genes (Carcereri De Prati A. et al., 2005). 
Despite some reports indicate the critical involvement of the change in redox state in 
modulating STAT1 activation (Grimm M. et al., 2002; Kim H. et al., 2001; Pawate S. 
et al.,2004; Pointer M. E. et al., 1999), our results show that all catechins present in 
green tea extract, excluding EGCG, are unable to down-regulate STAT1 activation, 
suggesting that EGCG may not exert its activity using exclusively its antioxidant 
capacity. 
In this work we have tried to answer two questions on:  
1. the structural features of the catechins for their anti-STAT1 activity; 
2. the molecular target and mechanism of action of the catechins in inhibiting 
STAT1 activation. 
New synthetic catechins, obtained by GCG chemical modification, was synthesized 
to answer these questions; as first, a study to understand a structure activity 
relationship has been done. 
The stereochemistry of the catechin gallate compounds does not influence the anti-
STAT1 activity. As a matter of fact, GCG, trans diastereomer of EGCG, is able to 
inhibit STAT1 activation and presents DNA-binding inhibitory level in EMSA assays 
(IC50 10-15 µM) similar to that of EGCG. Compound 2, lacking in one hydroxyl 
group in 5 of ring A, have similar anti-STAT1 activity (IC50 17 µM) in comparison to 
compound 1, racemate of GCG, (IC50 12 µM ). 
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Compound  3, lacking in both the hydroxyl groups in 5 and 7 of ring A, shows a 
lower anti-STAT1 activity (IC50 28 µM). Compounds 7, 8 and 9, that present two 
hydroxyl groups in R7 and R8, or two hydroxyl groups in R6 and R8 or only one 
hydroxyl group in R7 of ring D, retain a reduced anti-STAT1 DNA-binding activity 
(IC50 33, 37, 31 µM, respectively). Since compound 10, lacking in all hydroxyl 
groups in ring D, is completely inactive, at least one hydroxyl group in ring D must 
be  essential for the anti-STAT1 activity. 
The synthetic catechins lacking in hydroxyls in ring B (compounds 4, 5 and 6) are 
fully inactive, this indicates that the natural structure of ring B must be preserved to 
retain the inhibitory action on STAT1 activation.  
More than one hydroxyl group was removed simultaneously in rings A, B and D in 
compounds 11, 12, 13, 14 and 15. Compounds 11, 12 and 13 are characterized by 
removal of hydroxyl groups in rings A and B, while in compound 14 has been 
modified only rings B and D and in compound 15 has been modified rings A, B and 
D. All these compounds resulted inactive, thus confirming the importance of the three 
substituents of ring B for the STAT1 inhibition. 
Western blot studies demonstrate the ability of the synthetic compounds, lacking in 
some hydroxyl substituents, to inhibit the IFN-elicited STAT1 phosphorylations in 
Tyr701 and Ser727, that are necessary for STAT1 activation and for a maximal 
transcriptional activity. These analysis confirm the results obtained in EMSA assays 
and show that the chemical features for anti-STAT1 activity are: the presence of three 
hydroxyl groups in ring B and at least one hydroxyl group in ring D.  
IFN-elicited activation of STAT1 is correlated to acute inflammatory diseases, such 
as heart ischemia/reperfusion injury (Takagi Y. et al., 2002; Stephanou A. et al., 
2003; West D.A. et. Al., 2004), and chronic inflammatory diseases such as asthma 
(Sampath D. et al, 1999; Quarcoo D. et al., 2004), AIDS (Magnani M. et al., 2003; 
Miller E. D. et al., 2003), atherosclerosis (Wang X. Q. et al., 2002; Woods M. et al., 
2003), celiac disease (Mazzarella G. et al., 2003; Monteleone I. et al., 2004), chronic 
inflammatory bowel disease (Schreiber S. et al., 2002), diabetes (Cottet S. et al., 
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2001; Suk K. et al., 2001), psoriasis (Giustizieri M. L. et al.,2002) and rheumatoid 
arthritis (Yokota A. et al., 2001; Kasperkovitz P. V. et al.; 2004).  
The inhibitory effects of catechins against IFN-elicited STAT1 phosphorylation is 
important to block the expression of some STAT1 dependent genes, deeply involved 
in mediating inflammatory processes. iNOS, normally silent, seems to be involved in 
the pathology of several human diseases (Kroncke K. D. et al., 1998). Massive 
amount of NO produced by iNOS may lead to tissue damage (Miwa M. et al., 1987).  
Preliminary experiments showed that in human mammary carcinoma cell line MDA 
MB 231, iNOS induction strictly depends on IFN signaling and STAT1 activation, 
nevertheless LPS and cytokines such as TNFα and IL1β have synergistic effects for 
full iNOS expression by NF-κB activation. Although the activation of STAT1 is not 
exclusively elicited by IFN but by other cytokines (IFN α/β and IL10; Seidel H. M. 
et al., 2000), the biological effects of IFN are mainly mediated by STAT1 
homodimers (Meraz M. A. et al,1996 ). In this work MDA MB 231 cells were 
induced for 30 hours only with IFN to exclude the involvement of other transcription 
factors. The IFNγ-induction of MDA MB 231 cells was not the best condition for 
iNOS expression since it leads to an induction of only two fold. Nevertheless, we 
showed that compounds 1, 2, 3, 7, 8 and 9 were able to inhibit iNOS induction with 
different degree. All other compounds, as compound 5, lacking in one hydroxyl 
substituent in ring B, or compound 10, lacking in all hydroxyl groups in ring D, are 
unable to induce iNOS expression.  
Despite non-immune cells normally lack constitutive expression of MCH class II 
DRA gene, this gene expression in MDA MB 231 cells, can be induced by IFN. The 
regulation of MHC class II genes family occurs primarily at the transcriptional level; 
the master control factor for MHC class II transcription is class II transactivator 
(CIITA) (Rohn, W. M., 1996). IFN induces the expression of CIITA gene (Chang C. 
H. et al., 1994, Steimle V. C. A. et al., 1994). Thus, MCH II DRA expression in non-
immune cells may indicate an inflammatory state, which can compromise the 
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integrity of the tissue. The inhibition of these gene expression can improve organ 
condition and inhibit graft failure. 
Although MCH II DRA induction is under the control of different transcriptional 
factors (Meraz M. A. et al, 1996; Hobart M. et al., 1997), a single treatment of MDA 
MB 231 cells with IFN gives a full induction of MCH II DRA gene expression. In 
this experimental condition, compounds 1, 2, 3, 7, 8 and 9 completely inhibit MCH II 
DRA expression to the levels of non-induced cells. The others catechins, lacking of 
the previously mentioned chemical features, present an irrelevant capability to inhibit 
MCH II DRA expression. 
These data reinforce the previous evidences obtained by EMSA and Western Blot 
showing that the minimal structure of catechins for the inhibition of STAT1 
dependent genes expression is the presence of three hydroxyl groups in ring B and 
one hydroxyl group in ring D.  
The importance of modulation of iNOS, MCH II DRA and other STAT1 dependent 
genes expression involved in inflammatory and immune response is well known 
(Bach E.A. et al, 1999; Chatterjee-Kishore M. et al,2000 ). Our catechins may play a 
significant role to control these inflammatory processes. 
The second aim was to identify the molecular target of inhibitory action of catechins 
in the IFN/JAK/STAT1 pathway. Our results demonstrate that the earlier event in 
this pathway concern the inhibition of STAT1 phosphorylation. Thus, the possible 
targets of this inhibition could be upstream: IFN binding to its specific receptor 
(IFNGR1/2), and JAK Tyrosine phosphorylation, or  STAT1 Tyrosine 701 and Serine 
727 phosphorylation itself. 
The possible interaction of the catechins with IFNGR was not evaluated. Previous  
studies with radiolabelled catechins showed the ability of these compounds to enter 
into the cell (Okabe S. et al., 1997). Moreover, our preliminary results showed action 
of GCG also after washout catechins by changing cell medium, suggesting that the 
molecular target might be an intracellular protein.  
Discussion 
82 
 
Activation of JAK 1 and 2 by tyrosine phosphorylation is reported to cause STAT1 
and STAT3 activation (Leonard W. et. Al, 1998). Since EGCG and GCG fail to 
inhibit interleukin6-elicited activation of STAT3 in the same cell line (Menegazzi M. 
et al., 2001), the possibility that catechins reduce JAK1 or 2 activity to inhibit STAT1 
phosphorylation is unlikely. Involvement of tyrosine phosphatases in STAT1 
inhibitory action of catechins also seems to be quite improbable, since they may 
regulate the tyrosine-phosphorylated state of a wide spectrum of proteins including 
STAT3. SOCS1/3, that down-regulate STATs activation, could be a target of 
catechins. Since the notion that SOCS gene expression is induced mainly by STAT1 
activation itself renders this possibility unlikely. 
We took into account the idea that the target of  STAT1-inhibiting action of catechins 
might be STAT1 protein itself. To evaluate this hypothesis first we analyzed, by 
Surface Plasmon Resonance method, the interaction between immobilized STAT1 
and all different catechins. SPR analysis indicate that EGCG, GCG and the synthetic 
catechins with the presence of three hydroxyl groups in ring B and, at least, one 
hydroxyl group in ring D, directly interact with STAT1 protein with high affinity. 
Moreover, EGCG, GCG and compounds 1, 2 and 3 present two KD values (nM and 
µM) which lead to suppose the presence of two binding sites with different affinities 
on STAT1 protein. These data are in line with computer modelling analysis 
indicating that GCG may strongly interact with STAT1 at two sites, site 1 and site 2, 
close to SH2 domain. This binding could affect the tyrosine 701 phosphorylation.  
Site-directed mutagenesis shows that site 2 has higher affinity for catechins than site 
1, as replacing His568 of site 2 with Ala, KD1 (nM) disappears. Probably this amino 
acid is important to save the binding pocket for catechins, which seemed to be 
stabilized by His568 bound to opposite α chain domain. On the other hand without 
His568 there is no interaction with hydroxyl groups of ring B of catechins in site 2. 
Moreover, this mutation probably provokes a structural change in all STAT1 protein 
so that to decrease the binding affinity of the catechins for STAT1 protein also at site 
1, as shown by the nearly 10 fold increase of KD2 values.  
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Since synthetic catechins 4, 5, 6, 10, 11, 12, 13, 14, 15 have not inhibitory action on 
IFN-elicited STAT1 activation,  and they are unable to directly interact with STAT1, 
we suggest that the three hydroxyl groups in ring B are critical for their specific 
binding to STAT1. The docking analysis data seem to support this hypothesis 
showing different orientations of active and inactive catechins in STAT1 binding 
sites. The compounds able to inhibit IFN-elicited STAT1 activation seem to direct 
the three hydroxyls of ring B into the cavity, stabilizing catechin-STAT1 complexes. 
The compounds unable to inhibit STAT1 activation, seem to orient the ring B toward 
the outside of  the cavities of STAT1 pocket.  
This data may suggest that inhibitory action of considered catechins on STAT1 DNA-
binding activity is due to its capacity to strongly and directly interact with STAT1 
protein. The ability of anti-STAT1 catechins to directly interact with STAT1 with 
high affinity at critical sites close to SH2 domain underlines a novel mechanism 
leading to an efficient and specific inhibition of STAT1 activation. In particular, the 
very high affinity of the compounds 1, 2 and 3 towards putative binding site 2 is in 
line with the specificity of their action towards the STAT1 pathway shown in this 
study. Since, STAT3, having a slightly different SH2 domain with respect to that of 
STAT1, was not inhibited by anti-STAT1 catechins, adding further support to the 
above-mentioned mechanism. This may also explain how anti-STAT1 catechins 
disturb IFN-elicited phosphorylation of  both Tyr701 and Ser727, both of which are 
situated near putative anti-STAT1 catechins binding sites.  
Our results obtained by Western Blot analysis showed that MDA MB 231 cells, pre-
treated with active catechins, had lower level of phosphorylated STAT1. This was 
confirmed by STAT1-JAK2 kinase assay data showing that the “in vitro” STAT1 
phosphorylation in Tyr701 is inhibited, in a dose dependent manner, by catechins’ 
pre-treatment. On the contrary, JAK2 auto-phosphorylation does not change after pre-
treatment with active catechins in presence of STAT1, suggesting that STAT1 is the 
real target of inhibitory action of these compounds. Therefore, this assay supports the 
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idea that direct binding of the anti-STAT1 catechins with STAT1 protein is an 
important event to affect STAT1 phosphorylation in Tyr701 by JAK2 enzyme. 
In conclusion our results indicate that the inhibitory action of anti-STAT1 catechins 
should not be attributed only to their antioxidant activity. This work indicates that 
among a number of catechins examined, the compounds with a common structural 
features including the presence of three hydroxyl groups in ring B and at least of one 
hydroxyl group in the ring D are able to inhibit STAT1 activation. Among all the 
possible targets in IFN/JAK/STAT1 pathway, this chemical features allow catechins 
to directly interact with STAT1 protein. The catechins-STAT1 interaction is very 
tight and seems to prevent STAT1 phosphprylation in Tyr701 by JAK2, and represent 
a novel, specific and efficient molecular mechanism for inhibition of IFN-elicited 
STAT1 activation. 
This study, furthermore, may be considered the first step to the development of new 
anti-STAT1 molecules, able to prevent or to switch off inflammatory diseases.    
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